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ABSTRACT
Treatment for maternal hyperglycemia is limited on account of safety concerns
for the fetus. Our previous work has shown that inclusion of resistant starch in the diet
decreases body fat accumulation in rodents, increases GLP-1 at both the gene
expression level and plasma levels, and improves glucose tolerance in STZ-induced
diabetic mice. However, studies concerning dietary resistant starch and maternal
hyperglycemia are scarce. In this project, we examined the effects of dietary resistant
starch in pregnant Goto-Kakizaki (GK) rats to improve glycemic control. We
hypothesized that 1) dietary resistant starch could improve maternal glycemic control in a
type 2 diabetes model –GK rat; 2) the favorable changes in dams would benefit offspring
in terms of glucose metabolism.
Two animal experiments were conducted to test the hypotheses. In study 1, the
female GK rats were randomly grouped to receive an energy control diet or resistant
starch diet. The aged matched female Wistar rats were fed an energy control diet, serving
as glycemia control. After 10 weeks on the assigned diets, all the female rats were mated
with male Wistar rats and became pregnant. Fasting glucose concentration and fasting
insulin concentration were measured on the 16th gestation day. In study 2, the offspring
from different dams were fed on a chow diet until they reached 8 weeks old. At the end
of the studies, body fat, glucagon-like peptide -1 (GLP-1), pancreatic insulin content,
cecum pH, cecal short chain fatty acids levels, cecal butyrate producing bacterial profiles
and ß cell mass were measured.
Resistant starch fed GK rats had decreased body fat, improved insulin
sensitivity (HOMA-IR), increased cecal short chain fatty acids and butyrate producing
bacterial levels, and elevated plasma GLP-1. Also, GK rats on RS diet showed higher
x

beta cell mass compared with EC fed GK rats. Body weight and food intake were not
changed by resistant starch. Offspring born to RS fed dams had lower fasting blood
glucose and increased pancreatic insulin content. The feeding of RS to pregnant GK
rats did not show negative impact on pup’s growth and fetus survival rate. The
conclusions are that dietary resistant starch was able to improve maternal
hyperglycemia control in pregnant GK rats and decreased fasting glucose of their
offspring without negative influences on growth and fetus survival rate.

xi

CHAPTER 1
INTRODUCTION
The worldwide prevalence of diabetes has risen dramatically during the past two
decades, especially in the United States. The 2007 national diabetes fact sheet (CDC,
2007) showed that 7.8% of the total population has diabetes, which is a 0.8% increase in
two years (7.0% in 2005). With the incidence of diabetes hitting an all-time high,
maternal hyperglycemia is becoming a health threat to pregnant women. Among 23.6
million people who suffer from diabetes at all ages, 23.5 million are age 20 and older,
11.5 million are women, a high portion of which are young patients whose ages fall in
the range of 20 to 39, which happens to be the period of child bearing. In 2007, 281,000
new cases of diabetes were diagnosed in people aged from 20 to 39 years old (CDC,
2007). Maternal hyperglycemia not only brings negative impacts to pregnant women, but
also an independent risk factor for negative fetus/infant’s health conditions. Currently
limited treatments are available for the safety concerns of the fetus. Therefore, it is
important and urgent to find effective interventions to maternal hyperglycemia.
Resistant starches are non-digestible fermentable dietary fibers that resist
digestion in the small intestine, but are fermented in the large intestine. It has been shown
that adding resistant starch to diets produces several health benefits, including lower body
fat storage (Shen et al, 2009; Keenan et al, 2006), and decreasing plasma glucose in
rodents (Zhou et al, 2008). However, the knowledge on dietary resistant starch and
maternal hyperglycemia is incomplete.
In addition to the conventional effects as dietary fiber, such as diluting the energy
density of the diet and causing discomfort in the gut, resistant starch fed animals were
also found to have significantly higher levels of glucagon-like peptide -1 (GLP-1)
1

( Keenan, et al. 2006; Zhou et al. 2006). The action of GLP-1, as a potent incretin,
includes stimulating proinsulin gene expression (Drucker et al, 1987), inhibiting glucagon
secretion (Nauck et al, 2002), mediating glucose-dependent insulin secretion via their
receptors expressed on beta cells (Drucker, 2006), inhibiting gastric acid secretion and
delaying gastric emptying(Baggio et al, 2004), as well as promoting an increase in
pancreatic β-cell mass through enhancing beta cell proliferation and inhibiting
apoptosis(Stoffers et al, 2003;Wang et al, 2002). GLP-1 was shown to be able to delay
the onset of diabetes and improve pancreatic insulin content and total beta-cell mass in
GK rats when applied postnatally for 5 days (Tourrel et al, 2002). GLP-1 also was
reported to reduce apoptosis in human islets (Farilla et al, 2003). A GLP-1 receptor
agonist demonstrated similar effects. Exendin-4 not only improved glucose tolerance in
diabetic rats via expansion of beta cell volume (Xu et al, 1999), but also prevented the
development of diabetes in rats exposed to intrauterine growth retardation (Stoffers et al,
2003).
The GK rat is a non-obese, polygenic model of type 2 diabetes derived from
Wistar rats by selective breeding for slightly impaired glucose tolerance (Goto et al,
1975). This type of rat is characterized by moderate hyperglucemia, hypoinsulinaemia,
normolipidaemia and impaired glucose tolerance which is thought to be the results
primarily of reduced beta cell mass and a defective insulin response to glucose (Portha,
2005; Movassat et al, 1997; Movassat et al, 2007; Movassat et al, 1995). This model
provides great opportunity to investigate the impact of dietary resistant starch on
pancreatic beta cells.
Over the years, there has been a growing body of evidence indicating that
intrauterine exposure to a hyperglycemic environment increased the risk of diabetes and
2

obesity for offspring later in their life in addition to any genetic transmission (Pettitt et al,
199; Waterland et al, 1999; Boney et al, 2005). A study also revealed that glycaemic
control in GDM pregnancies was an effective way to prevent impaired glucose tolerance
in childhood. Even minimal intervention made a difference (Malcolm et al, 2006).
The current studies have been conducted to address the following questions: what
would be the effects of dietary resistant starch on glycemic control in the pregnant GK rat?
If there is improvement this should occur by improving insulin sensitivity through
reducing body fat or through the involvement of GLP-1on pancreatic beta cell
functioning or both? Will the intervention influence their offspring? Will the possible
discomfort in gastricintestinal tract due to high levels of fermentation induced by dietary
resistant starch exert negative impact on gestation and the pup’s growth? The hypotheses
for this work are that 1) dietary resistant starch will improve maternal glycemic control in
the GK rat– type 2 diabetes model and the elevation of GLP-1 might be an important
factor invovled; and 2) the favorable changes in the dams will benefit the offspring in
terms of glucose metabolism.
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CHAPTER 2
REVIEW OF LITERATURE
2.1 Resistant Starch
2.1.1 General Introduction
Resistant Starches are dietary carbohydrates that resist digestion in the small
intestine and reach the large intestine where they are fermented by bacteria to produce
short chain fatty acids. Dietary resistant starches have been identified as possessing a
variety of health benefits, which include decreasing plasma cholesterol and triglycerides,
increasing satiety, producing anticancer effects, improving glucose tolerance, and
consistently reducing body fat both in rodents and humans. (Zhou et al, 2008; Keenan et
al, 2006; Brown 2004; Robertson et al, 2003; Shen et al, 2009).
However, the levels of resistant starch consumption have been progressively
decreasing due to modern milling and food processing methods, especially in developed
countries. Data show that in medieval Europe, the average intake of resistant starch was
as high as 50-100 g/day (Birket 1997). And currently the estimated number for
consumption of RS in developing countries is 30-40 g/day (Baghurst et al, 2001),
whereas only 3-8 g daily are consumed by people in developed countries (Baghurst et al,
2001; Brighenti et al, 1998; Dyssler et al, 1994).
The term resistant starch (RS), was first coined in 1982 (Ritter et al, 1989). RS is
divided into four subcategories: RS1, RS2, RS3, and RS4. RS1 represents starch in whole
grains that are in a physically inaccessible form. RS2 is a type of starch, such as
ungelatinized starch, which is tightly packed in a radial pattern in starch granules and
resists digestion. The high amylose cornstarch used in the current study is an example of
a RS2. RS3 is the type of starch that is most resistant to digestion. The starch fitting in
4

this category is mainly retrograded amylose formed in the process of cooling the
gelatinized starch and can escape the digestion of pancreatic amylase almost totally. RS4
includes structurally modified starch by chemical treatment linking amylose strands. In
our study, the starch used is composed of 60% amylose and 56% RS.
Recently dietary fermentable fibers have shown potential in the anti-diabetes field
as a natural agent (Robertson et al, 2005; Park et al, 2004; Zhang et al, 2007). Our
previous works show that dietary resistant starch possesses favorable impacts on gut
hormone profiles, including promoting GLP-1 release consistently, a potent anti-diabetic
incretin (Zhou et al, 2006). Also we demonstrated body fat was consistently lower in
resistant starch fed animals compared to control animals fed the same energy density diet
in rodents (Keenan et al, 2006; Shen et al, 2009). Additionally, we explored the effect of
RS on glucose metabolism and found it lowers fasting glucose, fasting insulin and
improves glucose intolerance (Zhou et al, 2008). Thus, resistant starch might be an
alternative agent in diabetes treatment.
2.1.2 Resistant Starch and Glycemic Control
2.1.2.1 Animal Studies
•

Feeding Resistant Starch Decreases Body Fat Accumulation in Rodents
Several studies demonstrated that rodents fed resistant starch had a significantly

lower body fat (Shen et al, 2009; Keenan et al, 2006; Zhou et al, 2009). The RS induced
body fat decrease is greater as higher levels of RS are in the diet and the longer the time
of consumption. This has been shown in two different strains of rats (Wistar unpublished
data; SD:Keenan et al, 2006) and in C57BL/6J mice (Zhou et al, 2009).
•

Dietary Resistant Starch Lowers Fasting glucose, Fasting insulin and Improves
Glucose Tolerance
C57BL/6J Mice fed RS had a significantly lower fasting glucose and insulin at 6
5

weeks (our unpublished data) .Diabetic mice induced by streptozotocin (STZ) were fed
RS or control diet for 14days. Compared to the STZ injected mice fed control diet, the
blood glucose levels and the area under the curve (AUC) during the OGTT significantly
decreased (P<0.05) in STZ induced diabetic mice on the RS diet (Zhou et al, 2008). A
study with 12 weeks of feeding dietary resistant starch to male GK rats inhibited glucose
dependant insulintropic polypeptide (GIP) mRNA expression in the small intestine,
improved fasting glucose level, but there was no significant change of GIP in the
circulation (Shimada et al, 2008). Dietary RS also showed a positive effect on glycemic
control in diet induced obese rats in a short interventional duration of 4 weeks. Aziz et al
found that a high amylose starch diet, compared with an amylopectin rich diet, led to
reduced fat mass, less incremental AUC of OGTT, decreased fasting serum glucose,
insulin, leptin, a higher insulin sensitivity index (QUICKI), and an elevated mRNA
expression of UCP-1(Aziz et al, 2009)
•

Dietary Resistant Starch Increases Circulating Gut Hormones
Elevated plasma GLP-1 was observed in both normal SD and diet induced obese

rats fed resistant starch (Shen et al, 2009; Aziz et al, 2009). And the GLP-1 increase is
consistent over a 24 hour period (Zhou et al, 2008). Gene exxpression data from our
group also verified that dietary RS dramatically up-regulated the expression of the GLP-1
gene in rat cecal cells compared to rats consuming an energy control diet (Zhou et al,
2006).
2.1.2.2 Human Studies
•

Effect of RS on Glucose Metabolism

¾ Long Term Studies
Several human studies have been published regarding the effect of RS on
6

glucose metabolism. Among these studies different participants were recruited, however,
the beneficial effects on metabolism were consistent and promising.
Early in 1995 de Roos et al found RS3 decreased insulin secretion while
supplementation of RS2 resulted in lower appetite scores. In their study, 24 healthy males
were supplemented with glucose, RS2 and RS3 for one week respectively and 48- hours
of urine was collected to determine C-peptide for the last 2 days of each week. Satiety
and food intake were measured using visualized analogue scale and a 24 hour recall
method (de Roos et al, 1995).
In 2005, Robertson et al conducted a single-blind, crossover dietary intervention
study in 10 healthy subjects that were given 30 g resistant starch per day for four weeks
(Robertson et al, 2005). The resistant starch was in a form of Hi-Maize 260 at 50 g/d (30
g type 2 RS and 20 g rapidly digestible starch), and the placebo was 20 grams of Amioca
starch which consisted of only rapidly digestible starch. The two starches were added to
participants’ habitual diet, separated by a 4-wk washout period. After RS treatment,
insulin sensitivity became higher compared with placebo treatment when assessed by
euglycemic-hyperinsulinemic clamp (p=0.03), and when using a meal tolerance test, it
was 33% higher (p=0.05), skeletal muscle glucose clearance was also significantly higher
(p=0.027). With resistant starch supplementation, subcutaneous abdominal adipose
tissue nonesterified fatty acid (NEFA; P = 0.02) and glycerol (P = 0.05) release were
lower than with placebo. However, plasma GLP-1 and leptin concentrations were not
significantly changed. Systemic acetate and propionate concentrations were significantly
higher (by repeated measure) as well as fasting plasma ghrelin with RS intervention.
A similar study in overweight subjects was published by Park et al in 2004 (Park
et al, 2004). It was a double –blind randomized study. The investigators recruited 25
7

overweight participants (defined by over 120% of their ideal weight), 12 in treatment and
13 in control, feeding them either amylose 24g each day for 21 days or the same amount
of regular corn starch with regular meals. At the end of the study, participants
supplemented with RS had lower total serum cholesterol, LDL-cholesterol, and fasting
serum glucose concentration (p<0.05).
Robertson and her coworkers did another randomized, crossover study in
overweight individuals with metabolic syndrome in 2009 (Robertson et al, 2009). They
recruited 10 overweight individuals with metabolic syndrome and fed them 40 grams of
resistant starch from Hi-maize per day for 4 weeks, and control regular starch for another
4 week, set apart by a washout period. By using an arteriovenous difference method, they
found the glucose clearance in forearm skeletal muscle was increased by 68% with
resistant starch supplementation. Moreover, the subjects who consumed RS had improved
hepatic insulin sensitivity and peripheral insulin sensitivity as well. These parameters
were all measured by the hyperinsulinemic-euglycemic insulin clamp and the indirect
meal tolerance test. The results of the latter also showed consumption of RS can reduce
fasting insulin levels, postprandial insulin responses to the meal, and fasting free fatty
acids concentrations.
Another study was done in 20 metabolic syndrome subjects with 40 grams a day
of resistant starch or placebo supplement (0 g/day) for 12 weeks by the same group
(Johnston et al, 2010). Resistant starch consumption improved insulin sensitivity
measured by euglycaemic-hyperinsulinaemic clamp, compared with the placebo group (P
= 0.023). However, this change was not accompanied by the alteration of fat storage in
muscle, liver or visceral depots and inflammatory markers.
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A randomized, crossover study in type 2 DM patients was conducted by Zhang et
al in 2007(Zhang et al, 2007). Forty type 2 diabetics were randomly assigned into group
A and group B. At stage I, group A received 30 g resistant starch from Hi-maize per day
for four weeks and group B served as control. In stage II, the two groups switched onto
the opposite treatments for the same period of time. With consumption of resistant starch,
fasting blood glucose, post prandial blood glucose, total cholesterol, and triglycerides
were significantly lower in the intervention group (P < 0.05). The insulin sensitivity
index calculated with fasting glucose and insulin concentrations was higher in the
intervention group than in the control group (P < 0.05) as indirectly measured by a meal
tolerance test.
¾ Short Term Studies
Robertson and her coworkers evaluated the short term effect of dietary resistant
starch on glucose metabolism in healthy subjects in 2003 (Robertson et al, 2003). In this
single-blind, crossover dietary intervention study, 10 healthy subjects were given a basal
diet either supplemented with 100 gram Himaize (consisting of 60 g RS and 40 g rapidly
digestible starch) or with 40 g of rapidly digestible starch for 24 hours. The starch was
mixed with jelly and served. Insulin sensitivity was assessed by meal tolerance test in
combination with the minimal model index. Prior RS consumption led to decreased
glucose excursion during the 5 hour MTT test as well as the insulin concentration.
Systemic insulin sensitivity was improved significantly (p=0.028). No significant effects
of dietary RS on plasma GLP-1, short-chain fatty acids and plasma triacyglycerol were
observed.
A double-blind, placebo-controlled, crossover dietary intervention study was
performed in participants with fasting blood glucose between 100mg/dl and 140mg/dl
9

(Yamada et al, 2005). Twenty subjects ingested bread either containing 6 gram of RS3 or
no RS separated by 2 weeks. Blood was drawn from subjects for blood glucose and
insulin measurement prior to ingestion and 0.5, 1, 1.5 and 2 hours following ingestion.
According to their fasting blood glucose, they were divided into a borderline group
(blood glucose≥111mg/dl) and a normal group. Postprandial blood glucose increase was
reduced significantly at 1 hour and 1.5 hour after ingestion of RS bread compared with
placebo. So was the insulin response. However, these changes occurred in the borderline
group and not in subjects from the normal group.
Achour and coworkers recruited 8 healthy subjects and gave them two test meals
at 0800 and 2200 respectively in a 27 hour period (Achour et al, 1997). The test meal
consisted of either 50g pre-gelatinized corn starch or 50g retrograded corn starch. As a
placebo-controlled, crossover dietary intervention study, the subjects had two test periods,
with one week interval between. The diet composition for the test meal and placebo meal
was the same except for the starch type. However, they didn’t count the difference in
metabolized energy between these two starches. An 8-hour period right after ingestion of
the first meal was designated as the absorptive period. The postabsorptive period was
defined as a 3 hour duration 10 hours after consumption of the second test meal. Fasting
blood glucose, insulin, glycerol, fatty acids, acetate and breath hydrogen, breath methane
were measured.
Blood glucose and insulin were lower with ingestion of retrograded starch in the
absorptive stage. No other siginificant differences were observed in blood acetate, free
fatty acids, respiratory quotient, breath hydrogen and breath methane. Blood glycerol was
lower after ingestion of pre-gelatinized starch. In the postabsorptive period blood glucose
and insulin were not different between the two meals. However, other measurements
10

were significantly higher or lower (glycerol) with retrograded corn starch except for the
free fatty acids concentration. They reported that fermentation occurred for 24 hours after
consumption as indicated by elevation of breath hydrogen and blood acetate. The result
was consistent with Liljeberg’s observation in 1999 that a 4 –hour digestion was not long
enough to observe fermentation of RS (Liljeberg et al, 1999).
•

Dietary Resistant Starch and Maternal Hyperglycemia
So far there is no study available that has investigated the effect of RS on

maternal hyperglycemia. However, there is evidence that dietary fiber intake was
strongly and inversely associated with gestational diabetes risk (n=13,110; 8 year followup) (Zhang et al, 2006). A low glycemic index diet has also been shown to significantly
decrease birth size, birthweight, and ponderal index of infants born to healthy mothers
(Moses et al, 2006). Table 2.1 summaries published human studies of glycemic index and
Maternal Hyperglycemia.
Table 2.1 Summary of published human studies of glycemic index and maternal
hyperglycemia
Purpose

Participant
#

LOW GI vs
high(conventional
high-fiber)
If reduce the need
of insulin
52% CHO
composed of low
and moderate
glycemic index in
controlling GDM
condition
The association
between total
dietary fiber
consumptions and
GDM

63 GDM

31 GDM
76% OB,
24% OW

758 GDM

Diet

Results

52%
carbohydrates ,
30% of fat,
18% of
proteins
4 months
prospective
cohort study
in the Nurses'
Health Study
II
11

Reference

(9/31) 29% vs
59%(19/32)
9/19 stop insulin after
changing to LGI diet

Moses et
al, 2009

GLU :146 +/- 37 vs 90
+/- 5 mg/dL
Hb1 A c: 7.1 +/- 1.2 and
5.0 +/- 0.7

Monroy
et al,
2008

10-g/day ↑~26% ↓ in
risk; 5-g/day ↑ in cereal
or fruit fiber ~ 23% (936) or 26% (5-42) ↓

Zhang et
al, 2006

(Table 2.1 con’d)
Improved insulin
economy based on the
lowered insulin
responses to the
intravenous glucose
challenge (35%)
No changes in fasting
levels of glucose,
insulin, HDL-cholesterol
or TG.
glycemic index was
positively related to
maternal Hb1Ac
(ß=0.004)and plasma
glucose(ß=0.163),p<0.05

Ostman
et al,
2006

Meta-analysis

Trial1: no difference
Trial2&3: fewer large
for gestational age
infants; lower ponderal
indexes: lower maternal
fasting glucose levels

Review
(Tieu et
al, 2008)

Observational
study
Total fiber

1. Higer fiber
intake(20.5g/d)vs lower
fiber intake(8.1g/d)
required 16%~18% less
insulin.
2. fiber intake was not
associated with FBS and
Hb1Ac

Kalkwarf
et al,
2001

Improving
glucose tolerance,
insulin sensitivity
and lipids file by
changing the
glycaemic index
(GI) and dietary
fibre (DF) content
of their bread

7 IGT
With
previous
GDM

Crossover
study
Low GI/high
DF vs high
GI/low DF for
3 week

influence of
different
glycemic index
diet on infant
birth weight, fetal
growth, and
biomarkers of
carbohydrate
metabolism
Trial 1: high-fiber
diets compared
with normal
pregnancy diets
Trial 2&3: LGI
diet compared
with high
glycaemic index
diet
Whether higher
dietary fiber
intake (water
soluble and
insoluble) is
associated with
lower insulin
requirements and
better glycemic
control

1,082
health
pregnant
women

Prospective
cohort study in
The Camden
Study

Trial 1:25
Trial 2&3:
87

141
pregnant
with 1DM

Scholl et
al, 2004

2.1.2.3 Possible Mechanisms
The mechanism involved in improving glycemic control by resistant starch is not
completely understood. As a part of the diet, RS potentially has three major effects
(Keenan et al, 2006): metabolizable energy dilution, a bulking effect and fermentation to
12

produce short-chain fatty acids and increase PYY and GLP-1 through nutrient-gene
interactions. Resistant starch dilutes the energy density of the diet, which may contribute
to better glycemic control by reducing caloric intake. However, in our previous studies,
we balanced the energy density in the two diets, RS and EC, to exclude the effects of
energy dilution, and still obtained a similar outcome. Another assumption is that
fermentation of resistant starch causes discomfort in the gut, which leads to decreased
food intake and less glycemic load after meals. Nevertheless, resistant starch fed animals
ate the same or more food than controls (Keenan et al, 2006; Zhou et al, 2008), which
counters the previous assumption. The data from our lab showed dietary resistant starch
reduced body fat, increased fatty acid oxidation and promoted energy expenditure in
rodents (Zhou et al, 2008). However, failure of fermentation wiped out the effects (Zhou
et al, 2009). We also demonstrated gene expression and plasma levels of GLP-1 and PYY
were elevated in the large intestine where fermentation occurs (Zhou et al, 2006). Thus,
the fermentation of resistant starch in the large intestine by gut microflora, which
produces the increase of short chain fatty acids and consequent increase of gut hormones ,
might be considered as a major factor for RS improving glucose metabolism.
•

Fermentation in the Gut
The process of fermentation of RS in the large intestine involves several groups

of bacteria. When RS reaches the hind gut, bacteria such as Bacteroides thetaiotaomicron
(Bacteroides spp), Bifidobacterium longum (Bifidobacterium spp) and some
Lactobacillus spp (Bird et al, 2000; Xu et al, 2003a; Louis et al, 2007b) will adhere to the
surface of starch molecules and begin to convert RS into their fermentation products. The
end products of Bifidobacterium spp and Lactobacillus spp in fermenting RS are lactate
and acetate, whereas acetate, propionate and succinate are produced by Bacteroides spp
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(Duncan et al, 2002; Louis et al, 2007a). However, fermentation does not end here. These
products are intermediate metabolites that will be further converted to butyrate by other
bacterial species (Duncan et al, 2004a; Duncan et al, 2004b).
The majority of the butyrate producing bacteria belongs to Clostridium cluster
IV/C. leptum group and Clostridium cluster XIV /Clostridium coccoides–Eubacterium
rectale group (Louis et al, 2007a; Sato et al, 2008). Some of them are capable of utilizing
acetate to produce butyrate, such as Coprococcus spp. and Roseburia spp. of Clostridium
cluster XIV and Faecalibacterium prausnitzii of Clostridium cluster IV (Duncan et al,
2002; Cani et al, 2007a). Others like Eubacterium hallii and Anaerostipes caccae are able
to catalyze both the D and L isomers of lactic acid to butyrate (Duncan et al., 2004b),
whereas Eubacterium limosum can convert lactate into acetate and butyrate with the
presence of Bifidobacterium longum (Sato et al, 2008).
• Increase of Glucagon-Like Peptide -1
It is reported that resistant starch fed animals have significantly a higher level of
glucagon-like peptide -1 (GLP-1) (Keenan, et al. 2006; Zhou et al. 2006). GLP-1 is a
satiety peptide yielded from the pre-proglucagon gene product in the L enteroendocrine
cells of the distal intestine (Badman et al, 2005)
GLP-1 has several forms in the circulation. The inactive forms, GLP-11-36 and
GLP-11-37 , are cleaved from preproglucagon, depending on whether the C-terminal
glycine is present. Further N-terminal truncation is required to produce the biologically
active forms, GLP-17-36 and GLP-17-37 (Mojsov et al. 1986).
GLP-1 is released into the circulation in a biphasic manner in proportion to the
calories ingested (Orskov et al. 1994). The early phase release seems to be mediated by a
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neuroendocrine reflex, whereas the latter is a result of the presence of undigested
nutrients present in the lumen of the ileum or large intestine with L-cells.
The action of GLP-1, as a potent incretin, including mediating glucose-dependent
insulin secretion via their receptors expressed on beta cells (Drucker, 2006), stimulating
proinsulin gene expression (Drucker et al, 1987), inhibiting glucagon secretion (Nauck et
al, 2002), inhibiting gastric acid secretion and delaying gastric emptying(Baggio et al,
2004), as well as promoting an increase in pancreatic β-cell mass through enhancing beta
cell proliferation and inhibiting apoptosis(Stoffers et al, 2003;Wang et al, 2002).
GLP-1 was shown to be able to delay the onset and improve the severity of
diabetes in GK rats when given postnatally. GK rats with daily injections of glucagonlike peptide-1 (400 microg x kg(-1) x day(-1)) from day 2 to day 6 exhibited higher
pancreatic insulin content and total beta-cell mass than control rats. There were long term
effects observed in the same study: lower basal plasma glucose and slightly increased
glucose stimulated insulin secretion were found two months later in treated GK rats
(Tourrel et al, 2002). GLP-1 also was reported to reduce apoptosis in human islets
(Farilla et al, 2003). A GLP-1 receptor agonist demonstrated similar effects. Extendin-4
not only improved glucose tolerance in diabetic rats via expansion of beta cell volume
(Xu et al, 1999), but also prevented the development of diabetes in rats exposed to
intrauterine growth retardation (Stoffers et al, 2003).
•

Short Chain Fatty Acids (SCFA)
The main products of fermentation of dietary fibers in the mammalian gut are

SCFA including acetate, propionate, and butyrate (Morita et al, 1999). The typical ratios
of acetate to propionate to butyrate in feces are 3:1:1(Duncan et al, 2002). Normally,
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acetate is circulating in the bloodstream in a concentration around 100–150 µM, 4–5 µM
for propionate, and 1–3 µM for butyrate (Wolever et al, 1997).
A supplement of sodium butyrate facilitated fatty oxidation and increased energy
expenditure in mice; it protected mice from insulin resistance and hyperglycemia in diet
induced obesity (Gao et al, 2009). As one of the products from fermentation, it is
speculated that butyrate might be a key factor to mediate the RS signal to regulate
glucose metabolism. RS probably increases butyrate producing bacteria in the lower gut.
The elevated butyrate appears to stimulate GLP-1 expression and release from Lenterocytes through HDAC inhibition (Zhou et al, 2006). Increased GLP-1 signals to the
hypothalamus to upregulate hypothalamic POMC (Shen et al, 2009) which is an
important neuropepetide in promoting energy expenditure (Santini et al, 2009). In
addition, GLP-1 was reported to induce cAMP in hepatocytes (Ding et al, 2006), so it
may upregulate peroxisome proliferator–activated receptor (PPAR)-γ coactivator (PGC)1α activity through the PKA-CREB pathway (Puigserver et al, 2003; Lin et al, 2005).
PGC-1α is a transcription coactivator, which controls energy metabolism by targeting
several transcription factors of genes involved in fatty acid oxidation and mitochondrial
function which are essential in glucose metabolism (Lin et al, 2005).
After being transferred to blood stream, butyrate fed in the diet may directly
activate PGC-1α and uncoupling protein (UCP)-1 in brown fat, PGC-1α and adenosine
monophosphate-activated protein kinase (AMPK) in muscle and liver cells (Gao et al,
2009). In the muscle, PGC-1α increases fatty acid metabolism (Lin et al, 2002). In brown
fat, PGC-1α enhances adaptive thermogenesis through upregulation of UCP-1 expression
(Puigserver et al, 1998). UCP-1 diverts energy from ATP synthesis to thermogenesis to
increase energy expenditure. It has been shown that AMPK and p38 is responsible for
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upregulating PGC-1α activity in the post-translational phase (Knutti et al, 2001; Jager et
al, 2007). Butyrate was demonstrated to increase PGC-1α expression through both ways
(Gao et al, 2009). In addition, AMPK is an important regulatory sensor promoting fatty
acid oxidation and glucose metabolism (Gruzman et al, 2009).
As a histone deacetylase inhibitor, butyrate may also activate PPARα in
peripheral tissues. In vitro, butyrate enhanced the transcriptional activity of PPARα in a
dosage dependent manner. PPARα plays a critical role in activation of mitochondrial βoxidation of fatty acids through regulation of genes encoding key enzymes such as
carnitine palmitoyltransferase I, acetyl-CoA synthase and so on (Komatsu et al, 2010).
PPARα interacts with PGC-1α in metabolically active tissues including liver, skeletal
muscle, and brown fat and induces the expression of PPAR target genes (Vega et al,
2002). In liver and muscle, PGC-1α facilitates PPARα in the regulation of fatty acid
oxidation. In liver, they cooperatively control glucose production (Berger et al, 2002;
Francis et al, 2003). However, further study is needed to identify whether PPARα and
PGC-1 are required for butyrate induced energy expenditure.
2.2 Maternal Hyperglycemia
2.2.1 Current Problems
The worldwide prevalence of diabetes has risen dramatically during the past two
decades, especially in the United States. The 2007 national diabetes fact sheet (CDC,
2007) showed that 7.8% of the total population has diabetes, which is a 0.8% increase in
two years (7.0% in 2005). Among 23.6 million people who suffer from diabetes at all
ages, 23.5 million are age 20 and older, 11.5 million are women, quite a portion of which
are young patients whose ages fall in the range of 20 to 39, which happen to be the period
of child bearing. In 2007, 281,000 new cases of diabetes were diagnosed in people aged
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from 20 to 39 years old (CDC, 2007). In context of the current diabetes prevalence,
maternal hyperglycemia is becoming a health threat to pregnant women worldwide,
which consists of diabetic pregnant women (majority is type 2 diabetes) and those
diagnosed with Gestational Diabetes Mellitus (GDM). Maternal hyperglycemia not only
brings negative impacts to pregnant women, but also is an independent risk factor for
fetus/infant’s health conditions. Gestational diabetes mellitus, a special type of diabetes
in pregnancy, is further elucidated as follows.
2.2.1.1 Gestational Diabetes Mellitus
GDM is defined as the onset of glucose intolerance in a pregnant woman who has
not been diagnosed with diabetes before pregnancy. As a result of the increase in
prevalence, the severe adverse outcomes it brings to both mothers and their offspring, and
the limited treatment variety, GDM becomes a leading threatening factor to the health of
young women and their babies.
•

Increase of GDM incidence
The incidence of GDM is growing. It has doubled over the last few years and the

trend continues. In the United States, the rates per 1000 women have increased more than
3.5-fold among those aged 15–24 and 4 –fold in the age range 25–34 (Baraban et al,
2008). Data from the American Diabetes Association indicate gestational diabetes occurs
in about 4% of all pregnant women, with 135,000 new cases in the USA each year
(ADA.org). In 2006, the National Institute of Child Health and Human Development
estimated that GDM affects nearly 7 percent of all pregnancies (NIH.gov). The
prevalence of GDM has similar features to the obesity epidemic. 1. The incidence is
higher in urban versus semi-urban and rural areas in a developing country. Seshiah et al
conducted a study with a total of 41,513,960 participants in South India. They found the
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prevalence was 17.8% women in urban, 13.8% in semi-urban, and 9.9% in rural areas
(Seshiah et al.2008). 2. In the same ethnic groups, people who live in s developing
country have a lower prevalence than those who immigrated to western countries (2.7%
vs 7.3%) (Yang et al, 2002).
•

Adverse Outcomes
GDM has severe effects on both mothers and their offspring. Mothers with GDM

have an increased lifetime risk of developing type 2 diabetes mellitus (DM). According to
data reported by CDC, 5 to 10 percent of women with GDM will be diagnosed as type 2
DM right after pregnancy. Even for those women who return to a normal glucose
metabolism, they still have a 20 to 50 percent chance of developing diabetes in the next 5
to 10 years. (http://www.cdc.gov/diabetes/pubs/interim/background)
As for the infant, GDM has a more complicated impact. In the short-term, infants
born to parents with GDM have a higher chance of having macrosomia and
consequenced dystocia, developing respiratory distress syndrome and jaundice, stillbirth,
and dying in infancy. For the long-term, GDM is a significant risk factor for development
of obesity and abnormal glucose metabolism in their late life (Metzger, 2007).
It was shown that infants of GDM mothers had significantly greater skinfold
measures as well as fat mass, even when they are not macrosomic, compared to those of
mothers with normal glucose tolerance (Catalano et al, 2003). The increase of fetal
adiposity is thought to be a predictor for obesity in early childhood (Simmons, 2008).
The study of 552 Pima Indian offspring of GDM patients aged 5-24 yr showed that
a 1 mM higher maternal 2-h glucose level resulted in a higher occurrence of diabetes in
the offspring (odds ratio = 162) (Pettitt et al, 1991). The observation was not only limited
to Pima Indians, but also occurs in the general population. Children who are exposed to
19

an intrauterine environment of a high glucose concentration are at increased risk of
developing metabolic syndrome: 50% of the GDM group confirmed more than 2
components of metabolic syndrome, which was significantly higher than the control
group, 18% (Boney et al, 2005). One study revealed that glycaemic control in GDM
pregnancies is an effective way to prevent impaired glucose tolerance in childhood. Even
minimal intervention will make a difference (Malcolm et al, 2006).
•

Limited treatment variety
So far, treatment for GDM is limited only to nutrition intervention and insulin.

Nutrition therapy is the primary treatment for about 70-90% of women with gestational
diabetes mellitus (Gunderson, 2004). It has been recognized as the cornerstone of therapy
for GDM at worldwide conference (Metzger, 1998). The goal of nutrition therapy is to
achieve a balance between adequate nutritional needs and optimal glycemic control.
Although caloric restriction of 35-40 percent of total calories is effective for treatment for
GDM (Major et al, 1998), ADA suggests that it should be done with great caution
because of ketonemia and ketonuria, which can harm the fetus (American Diabetes
Association, 2002). Moreover, compared to numerous treatments available for Diabetes,
insulin is the only currently FDA approved medication for GDM. Therefore, new
treatments for GDM are necessary.
2.2.2 Mechanisms of Insulin Resistance in Maternal Hyperglycemia
Insulin resistance is thought to be the potential pathophysiology for GDM
(Buchanan et al, 2007). Progressive insulin resistance is present during normal
pregnancy due to elevated placental hormones and increased maternal adiposity (Barbour
et al, 2007). It usually begins near mid-pregnancy and reaches to the levels approaching
what seen in type 2 diabetes in the third trimester. Therefore, pregnancy is considered as
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a "diabetogenic state "(Zavalza-Gómez AB et al, 2008). There is molecular evidence that
with GDM there is greater insulin resistance than with normal pregnancy (table 2.2). So
GDM occurs when people who already have a chronic insulin resistance background
undergo the “diabetogenic state.”
Table 2.2 Comparison of normal pregnancy and gestational diabetes in terms of insulin
resistance
GDM
Normal
pregnancy
Insulin stimulated
Change of glut4
Glucose transport
protein is
(Friedman, 1999)
65% ^↓
40% *↓
Muscle
undetectable
Adipose(okuno, 1995)
Tyrosine phosphorylation
of IR ^( Friedman, 1999)
Activity of IR
pretreated with insulin(shao,2000a)*

GLUT4 ↓↓
↓
↓↓

↓

Partially restored
by alkaline
phosphatase

IR-1 protein*
Muscle(Friedman, 1999)

↓↓

Adipose(Catalano,2002)

↓

Antepartum
Postpartum
Serine phosphorylation
of IRS-1^ (Barbour, 2006)
P85αmonomer(Catalano,2002)

↓
_

52%↓
Back to
normal
62% ↑

Restored to normal

↓
No change
No change
No change
_

S-IRS-1/Total IRS-1

↑*

^ compare with normal pregnancy; * Compare
with nonpregnant obese
women
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↑*

2.2.2.1 Pregnancy Induced Insulin Resistance
Insulin resistance identified in pregnancy returns to normal soon after pregnancy
and so do the signaling changes in women with normal glucose tolerance. These findings
suggest that pregnancy per se is capable of inducing insulin resistance. As for mechanism,
several lines of evidence suggest that the physiological insulin resistance induced by
pregnancy could be caused by post-receptor defects and appear to be multifactorial (Boyd
et al, 2007). Normally, insulin binds to the α subunit of the insulin receptor, and
catalyzes autophosphorylation of the β-subunit of the insulin receptor at tyrosine residues,
then the activated receptor docks the insulin receptor substrate and tyrosine
phophorylates this protein, followed by recruiting of P85 of phosphatidylinositol 3-kinase
(PI3), production of PIP3 and signaling for GLUT4 translocation (Aguirre et al, 2002).
However, in pregnant women, a significant decrease in insulin receptor tyrosine
phosphorylation in muscle has been identified. In the light of evidence that the tyrosine
phosphatase activity and receptor number are not changed (Friedman et al, 1999, Shao et
al, 2000a), and the pretreating insulin receptor with alkaline phosphatase could restore
insulin’s ability to activate tyrosine phosphorylation of the insulin recepotor (Shao et al,
2000b), it is suggested that increased serine phosphorylation of the insulin receptor and
subsequently competitively downstream insulin signaling plays an important role. At the
level of insulin receptor substrate-1(IRS-1), strong evidence is also presented for
activated IRS-1 serine phosphorylation (Qiao et al, 2002). IRS-1 serine phosphorylation
is not only able to accelerate its degradation, but also dampen PI3 kinase activity by
inhibiting recruitment of P85 subunit. Possible mechanisms include 1. Excessive
nutrients such as amino acid and glucose during pregnancy stimulate p70 S6K expression,
which increases serine phophorylation (Shah et al, 2006); 2. TNF- α augmented by both
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placenta and expanded adipose tissue during pregnancy upregulates JNK, and this can
catalyze phosphorylation on serine residues (Aguirre et al, 2000); 3. Both TNF- α and
growth hormone can suppress expression of peroxisome proliferator activated recptor
which is a transcription factor for adiponectin (Masternak et al, 2005, Qiao et al, 2005).
Aditionally, a decreased adiponectin level leads to increased activity of the mTOR
pathway, which also contributes to serine phosphorylation (Tzatsos et al, 2006).
In addition, the increased amount of the free p85α subunit of PI3 kinase appears
to be involved in the post receptor defects (Barbour et al, 2005). PI3 kinase has two
subunits, the regulatory p85α subunit and catalytic p110 subunit. IRS has to bind with
p85α- p110 heterodimer to activate this enzyme and produce PIP3. P85α monomers
block IRS docking the p85α- p110 heterodimer (Biddinger et al, 2006). Placental growth
hormone appears to be involved in the accretion of P85α monomers (Barbour et al, 2002).
2.2.2.2 Role of Placenta in Insulin Resistance
The placenta is a complicated and crucial fetal organ for fetal growth. It is in
contact with both maternal and fetal circulations through different surfaces. Therefore, it
could be influenced by changes of regulatory factors present in the two circulations and
as a feedback produces hormones and cytokines to act on mother and fetus (Desoye et al,
2007).
Normally, during gestation the placenta synthesizes and releases a variety of
cytokines which contribute to the low grade systemic inflammation, and together with
hormones secreted by the placenta as well, are necessary to induce maternal insulin
resistance (Barbour et al, 2004). This physiological insulin resistance in late pregnancy is
a critical adaptation designed to ensure the growing fetus has an adequate supply of
nutrients by blunting maternal glucose uptake.
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However, in a pregnancy complicated with diabetes mellitus, the abnormal
maternal metabolic environment may stimulate the overexpression of cytokines and
inflammatory- related genes in the placenta and this results in the increased circulating
concentrations of inflammatory cytokines (Hauguel-de Mouzon et al, 2006). There are a
high amount of insulin receptors expressed in the placenta. It has been suggested that,
during the pregnancy, altered maternal insulin lead to abnormal synthesis and secretion of
hormones and cytokines by the placenta by interacting with the syncytiotrophoblast, and
this contributes to maternal insulin resistance (Desoye et al, 2007).
A variety of hormones secreted from the placenta and circulated in high
concentrations have been shown to be able to influence the insulin sensitivity in
peripheral tissues and induce insulin resistance during pregnancy; Estrogen, progesterone,
human placental lactogen (hPL), and human placental growth hormone (hPGH) are
reported to be involved in the process. (Barbour et al, 2004; Nagira et al, 2006; Kühl ,
1998; Reis et al, 1997; Ryan et al, 1988).
In surgical postmenopausal monkeys, estrogen and medroxyprogesterone acetate
treatment led to enlarged adipocytes and diminished insulin sensitivity (Shadoan et al,
2007). It was suggested that a post-receptor mechanism of activation of JNK mediated by
the membrane estrogen receptor (ER) pathway and the subsequent serine phosphorylation
of IRS1 probably contribute to estrogen induced insulin resistance in 3T3-L1 adipocytes
(Nagira et al, 2006). Estradiol also decreased insulin sensitivity by down- regulating
muscle glucose transport 4 (GLUT4) in vivo; when at high concentrations similar to that
in pregnancy, it reduced GLUT4 expression by 30% at both mRNA and protein levels.
Time- and dose-dependent responses were observed as well in the L-6 cell line. (Barros
et al, 2008);
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The knockout of the progesterone receptor was reported to promote beta-cell
proliferation and improve insulin secretion in response to glucose injection in female
mice which overall showed ameliorated glucose homeostasis (Picard et al, 2002). In vitro,
progesterone was shown to inhibit glucose transport as well as reduce glycogen synthesis
and glycolysis regardless of the presence of insulin in muscle (Leturque et al, 1989). The
mechanism studies indicated that the inhibition was obtained by suppressing multiple
steps of insulin signaling which included decrease of IRS1 expression and suppression of
the PI3-kinase independent pathway of TC10 activation (Wada et al, 2010).
It has been postulated that human placental lactogen (hPL) is the major placental
hormone which reprograms the occurrence of insulin resistance. Human placental
lactogen (hPL) rises 30-fold during pregnancy (Brelje et al, 1993). As early as in 1967,
hPL was indicated to induce peripheral insulin resistance in normal male subjects (Beck
et al, 1967). Placental lactogen was considered one of the hormones that were related to
the postreceptor defect of insulin signaling during pregnancy (Ryan et al, 1988). The
opposite result occurred with ovine placental lactogen’s failure to deteriorate glucose
metabolism in skeletal muscle (Leturque, 1989). However, overall supportive evidence of
hPL as the key factor in insulin resistance during pregnancy is sparse. On the contrary,
more and more studies suggest the main effect of hPL is to induce the pregnancyassociated growth of pancreatic islets and insulin secretion (Yamashita et al, 2000;
Handwerger et al, 2000; Brelje et al, 1993).
Human placental growth hormone (hPGH) is another placental hormone related to
the occurrence of pregnancy –induced insulin resistance, and is so far the most likely
hormonal candidate which mediates the insulin resistance in pregnancy (Barbour et al,
2004). Human placental growth hormone rises up to eightfold during pregnancy and is
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free from regulation by growth hormone release hormone (GHRH) (Handwerger et al,
2000). Severe peripheral insulin resistance was observed in transgenic mice
overexpressing placental growth hormone (Barbour et al, 2002). Further research
indicated this insulin resistance was due to the increased expression of one of the subunits
of PI 3-kinase, p85 monomer, and subsequent disruption of PI 3-kinase activation in
skeletal muscle. (Barbour et al, 2004). PI 3-kinase activation is a critical step in the
insulin signaling pathway whose product is required for propagating signals for GLUT4
translocation. Phosphorylated insulin receptor substrate 1 (IRS-1) must dock regulatory
p85 subunit and the catalytic p110 subunit as a heterodimer in order to activate the
enzyme (Wymann et al, 1998). p85 competes with the heterodimer to bind IRS-1 at a
specific binding site and effectively prevents the access of the heterodimer to IRS-1 once
it succeeds (Barbour et al, 2004). The p85α heterozygous deletion mice (p85α +/–)
demonstrated p85α is a key mediator in the placental growth hormone’s induction of
insulin resistance. Placental growth hormone caused overexpression of p85α, diminished
insulin stimulated PI 3-kinase activity and increased insulin resistance in wild type mice;
whereas p85α+/–mice were protected from its influence as evidenced by maintained
global insulin sensitivity and PI 3-kinase activity ((Barbour et al, 2005).
In addition to hormones, the human placenta also synthesizes virtually all known
cytokines which may contribute to the inflammation in the whole body (Telejko et al,
2010). Kirwan and colleagues investigated the correlation between insulin sensitivity and
placental products that included tumor necrosis factor α (TNF-α), leptin, cortisol, human
chorionic gonadotropin, es-tradiol, progesterone, human placental lactogen, and prolactin
in pregnancy. They reported that in humans, among all variables they studied, only the
circulating plasma TNF produced by the placenta was inversely correlated highly with
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in vivo insulin sensitivity, while hPGH was not included in this study (Kirwan et al,
2002). In obese pregnant women a similar association was observed between increased
TNF-α in peripheral blood and insulin resistance (Challier et al, 2008). Infusion of TNF-α
in rat led to increased global insulin resistance, and blunted glucose uptake when
incubated with human skeletal muscle cells in culture (Frost et al, 2005).
Possible mechanisms were suggested. The first is that TNF-α is able to act as a
serine threonine kinase to catalyze insulin receptor (IR) and IRS-1 serine phosphorylation
which in turn inhibits their tyrosine phosphorylation (Barbour et al, 2006; Catalano et al,
2002). TNF - α activated JNK, which can phosphorylate IR and IRS-1 on serine residues
(Rui et al, 2001). The second possible mechanism is that TNF- α has been shown to
suppress PPAR expression in the 3T3-L1 cell line and inhibit adipocyte differentiation
(Zhang et al, 1996). PPAR-γ is a transcription factor, expressed in adipose tissue, and is
essential in regulation of insulin sensitivity, adipicyte differentiation, and lipid storage
(Joosen et al, 2006; Zeghari et al, 2000; Schoonjans et al, 1996). One of its important
target genes is adiponectin (Qiao et al, 2005). Adiponectin is viewed as an endogenous
insulin-sensitizer due to its favorable effect on glucose homeostasis through its receptors
in skeletal muscle and liver (Hara et al, 2005). Several studies indicated that circulating
adiponectin level decreased in obesity and insulin resistance animal models (Arita et al,
1999). Epidemiology studies show an inverse correlation between plasma adiponectin
concentrations and the degree of insulin resistance in obesity, type 2 diabetes, and GDM
(Weyer et al, 2001; Worda et al, 2004; Cseh et al, 2004)).
Leptin is another placenta cytokine widely studied. Although adipose tissue
secretes leptin as does the placenta during gestation, it is suggested that the major
changes in leptin in pregnancy are attributed to placental leptin production (Bajoria, et al,
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2002). Several studies reported leptin was correlated negatively with insulin sensitivity in
normal pregnant women and gestational diabetics ( McIntyre et al, 2010; Mastorakos et al
et al, 2007). However, divergent findings about cytokines and insulin sensitivity are not
scarce which may be due to variation in experiment design, methods adopted, and
different subjects recruited. (Briana et al, 2009).
Further study is still needed to explore later steps in the insulin-signaling pathway
and examine the complicated cytokine and hormone crosstalk between placenta and
enlarged adipose tissue.
2.3 Beta Cell Dysfunction
Impaired beta cell function as well as tissues insulin resistance are two etiologic
factors in type 2 diabetes, which counts for 90-95% of total diabetes. It was thought
insulin resistance was the primary cause because it was more frequently reported
preceding beta cell dysfunction in the pathogenesis of type 2 diabetes (Gerich et al, 1999).
Besides, insulin resistance is highly correlated with both BMI and type 2 diabetes,
therefore, it may link overweight with increasing glycemia (Balkau et al, 2002). It also
appears to induce beta cell dysfunction through beta cell exhaustion (Leahy et al, 2005).
However, Gerich and co-workers found impaired beta cell secretion were present in nondiabetic first degree relatives of type 2 diabetes patients (Gerich et al, 2003). Moreover,
compared with controls, the first degree relatives exhibited reduced first and second
phase insulin secretion but no difference in insulin resistance (Pimenta et al, 1995).
Albeit there is still gap in our knowledge, it is well accepted that progressive beta call
dysfunction is a necessary condition in the occurrence of diabetes (Marchetti et al, 2008).
2.3.1 Reduced Beta Cell Mass
Normally there are about one million islets of Langerhans which constitute
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approximately 2% by weight of the human pancreas (Bonner-weir et al, 2005). Several
types of endocrine cells coexist in the islets. Insulin secreting beta cells represent 60-80%,
glucagon secreting alpha cells are around 20%, pancreatic polypeptide containing PP
cells ~15%, somatosatin delta cells ~ 10%, and ghrelin secreting cells ~1% ( Wierup et al,
2002; Rhodes et al,2005). The beta cell mass is changed at different stages of life as a
result of dynamic balance among replication, size modification, neogenesis, and
apoptosis (Dor et al, 2004).
Although it was suggested that beta cell mass reduction is present in all type of
diabetes, studies yielded discrepant results due to the limited access to human pancreas
tissue, especially for type 2 diabetes (Stefan et al, 1982; Saito et al, 1978. Sakuraba et al,
2002). Recently, studies with available pancreas specimens from surgery and postmortem samples, supported that beta cell mass is reduced in type 2 diabetes. Butler and
his co-workers obtained 124 pancreatic autopsy samples from obese with/without
diabetes , lean with /without diabetes and obese with impaired fasting glucose and
examined their beta cell mass together with cell proliferation and apoptosis. They found
obese non diabetics had a 50% increase in relative beta cell volume and an increased
neogenesis from ductal tissue versus lean non diabetics; obese patients with diabetes or
impaired fasting glucose were associate with a 63% and 40% deficit respectively,
compared with obese non diabetics; lean patients with diabetes had a 41% less relative
beta cell volume than lean controls. Another important finding in this study is that the
reduction of beta cell mass is attributed to increased frequency of apoptosis other than
diminished replication (Butler et al, 2003). Marchetti et al. also observed elevated
apoptosis by significantly increased activity of cysteine-aspartic acid protease (caspase)
3 and caspase 8 in human diabetic beta cells, and metformin was reported to be able to
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reduce cell death and normalize caspase 3 and caspase 8 activity as well (Marchetti et al,
2004).
2.3.2 Impaired Insulin Secretion Function
The reduction of beta cell mass does not solely cause the progression of type 2
diabetes because in rodents with experimental pancreatectomy the removed up to 50% of
tissue still maintained normal glycemia. Therefore, alterations of insulin secretion
become another interest of research. It has been extensively reported that multiple
alterations of insulin release exist in type 2 diabetics which are characterized by a
defective insulin response to glucose (Kahn et al, 2003; Del et al, 2002; Lin et al, 2002).
Normally, glucose stimulated insulin release is biphasic process with a short early phase
and much longer second phase (Henquin et al, 2000; Del et al, 2002). In type 2 diabetics,
the commonly found alterations are reduced or absent first phase insulin secretion in
response to intravenous glucose, blunted release in the second phase, and delayed
response to an ingestion of a mixed meal (Kahn et al, 2003; Del et al, 2002). In addition,
the pulsatile pattern of insulin release is disrupted instead of taking place every 8-10
minutes superimposed on low frequency oscillations (Porksen et al, 2002; Schmitz et al,
2002).
According to a well recognized hypothesis, under physiological circumstance,
glucose stimulates insulin secretion through the following steps (Marchetti et al, 2008).
First, glucose enters beta cell with aid from transmembrane protein glucose transport 2,
and undergoes catabolism via glycolysis and the Krebs cycle, which produces reducing
equivalents. The reducing equivalents then are transferred to the respiratory chain, also
called the electron transport chain, to form a proton gradient across the inner
mitochondrial membrane which couples the electron transport chain with oxidative
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phosphorylation and results in synthesis of ATP. Secondly, augmented ATP
concentrations increase the ATP/ADP ratio which leads to the closure of the ATPregulated K+ channels. Next the depolarization of cell membrane opens voltagedependent Ltype Ca 2+ channel which causes an influx of calcium ions. Finally, the
elevated cytoplasmic calcium ion promotes exocytosis of insulin granules. The
alterations of mitochondrial in type 2 diabetics have been indicated as one mechanism of
the impaired glucose stimulated insulin secretion in addition to decreased expression of
the glut2 gene and reduced activity of glucokinase (Del Guerra et al, 2005). Beta cell
mitochondria in type 2 diabetes have a higher density volume and become swollen with
undefined membranes (Welsh et al, 2005; Anello et al, 2005).

Figure 2.1 Mechanisms of glucose-induced insulin secretion (Marchetti et al, 2008)
Besides, ATP concentrations were lower as well as the ATP to ADP ratio.
However, the protein expression of two mitochondrial complexes of respiratory chain,
complex1 and 5, were found increased in diabetic beta cells. An increase of uncoupling
protein -2 (UCP-2) protein expression was also reported in this study (Anello et al, 2005).
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Taken together, it is suggested that the activated UCP-2 might be a key factor leading to
lower ATP production and eventually insulin secretion impairment.
UCP-2 protein expression can be activated by superoxide (Krauss et al, 2003).
Several markers of oxidative stress, nitrotyrosine and 8-hydroxy-2-deoxyguanosine, were
shown higher in type 2 diabetes than control. Both of the markers were also found
correlated with the severity of defective insulin secretion in response to glucose (Del
Guerra et al, 2005). Other evidence indicating the involvement of oxidative stress include
reduced expression of manganese-superoxide, increased expression of protein kinase cbeta2 and nicotinamide adenine dinucleotide phosphate reduced-oxidase (reactive oxygen
species producing enzymes) in diabetic islet cells (Marchetti et al, 2004; Del Guerra et al,
2005). Decrease of the nitrotyrosine level and improvement of glucose stimulated insulin
secretion were observed when islets of type 2 diabetes were incubated with metformin
for 24 hours in vitro (Marchetti et al, 2004).Antioxidants improved impaired beta cell
function and apoptosis in isolated islets exposed to elevated glucose (Kaneto et al, 1996).
Amyloidosis may play a role in the pathology of diabetes. Epidemiological studies
found a high prevalence of amyloidosis in type 2 diabetes patients and a significant
correlation between pancreatic amyloid formation and Hba1c (Zhang et al, 2003;
Westermark et al, 1987). Pancreatic amyloid plaques formation is a feature of type 2
diabetes histopathology (Clark et al, 1987). The beta cell is almost the only cell that
expresses the islet amyloid polypeptide gene. The protein is co-secreted with insulin. It is
still not clear what kind of role amyloid plays in the pathogenesisi of type 2 diabetes.
Possibly, the high concentration of islet amyloid polypeptide which leads to the
formation of amylodosis is caused by increased production of insulin secondary to
hyperglycemia (Hoppener et al, 2006; Ritzel et al, 2007).
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Glucotoxicity may also be involved in diabetes. Prolonged exposure to elevated
glucose was demonstrated to exert a slow but irreversible effect on beta cells which
enhances apoptosis and exacerbates glucose stimulated insulin secretion (Robertson et al,
2000). Chronic hyperglycemia might decrease insulin gene transcription through its
negative impact on beta-cell specific transcription factors (Kaiser et al, 2003). Also
chronic oxidative stress was suggested as at least part of the mechanism underlying
glucotoxity (Tanaka et al, 1999).
Lipotoxicity is also a factor. Free fatty acids are necessary to maintain normal beta
cell function; however, elevated fatty acids could inhibit islet gene expression such as
GLUT-2 partially through transcript factor pancreatic-duodenum homeobox-1(Gremlich
et al, 1997). Lipotoxicity requires the presence of concommitant hyperglycemia to affect
beta cell function. Accumulation of long chain fatty acyl CoAs and increased production
of ceramide might mediate the deleterious effects of elevated free fatty acids (Prentki et
al, 2006).
Another fator is inflammation. Increased numbers of macrophages were found in
diabetic pancreatic islet (Ehse et al, 2007). Exposure to a type 2 diabetes milieu resulted
in human islets to release inflammatory factors such as interlukin 6, interlukin 8, and
macrophage inflammatory protein, which activated migration of monocytes and
neutrophils (Ehses et al, 2007). Further research is needed to determine whether
inflammation is a causal factor.
2.4 Animal Models of Type 2 Diabetes
2.4.1 General Introduction
The incidence of type 2 diabetes has reached a new record high and brings serious
socio-economic burdens. Over the last years, numerous researchers have been motivated
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to devote their efforts to the study of diabetes, and intense efforts have been performed
which greatly advances our knowledge. Appropriate experimental models are essential to
facilitate the research. The animal models of type 2 diabetes can be classified into five
categories: spontaneously or genetically derived, chemicals induced, diet induced,
surgical manipulation, and genetically engineered (Srinivasan et al, 2007). Due to the
advantages of reduced cost, ease of maintenence and breeding, most available models are
based on rodents. A list of animal models was summarized in table 2.1 and the GotoKakizaki Rat (GK) which was used in this dissertation would be discussed in detail.
Table 2.3 Summary of animal models of type 2 diabetes (adapted from Srinivasan et al,
2007)
Model class

Name

Obese

Genetically
derived

ob/ob mouse

Yes

ob

(lep )

db/db mouse

Monogenic defect of
leptin gene on
chromosome 6 in
C57BL/6J or C57BL/KS
mice. Autosomal
recessive mutation

Yes

Monogenic defect of
leptin receptor gene on
chromosome 4 in
C57BL/KSJ mice. The
C57BL/KSJ leprdb/+develops diabetes
during pregnancy.
Autosomal recessive
mutation

Yes

Polygenic model from
selective inbred for large
body size in Japan

(leprdb)

KK mouse

Origin

(kuo Kondo)
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(Table 2.3 Con’d)
KK/Ay mouse

Yes

(yellow KK obese
mouse)

New ZealandObese
mouse(NZO)

Tsumara Suzuki
Obese Diabetes
mouse (TSOD)

Yes

Yes

Zucker Fatty Rat
(leprfa)

Zucker
Diabetic Rat
(ZDF)
Otsuka Long
Evans
Tokushima
Fatty
Rat(OLETF)
Obese Rhesus
Monkey
Cohen
Diabetic Rat

Yes

Was developed from
cross breeding of Ay/a
(dominant mutation)
mice with one of the
inbred KK strains

An inbred strain of
polygenic model
selected for agouti coat
color
Polygenic origin inbred
from obese male ddY
strain

mutation of a single
autosomal recessive
gene on chromosome
5(fa)

Yes (less than
ZFR)

Substrain of ZFR inbred
for hyperglycemia

Yes

Polygenic rat model by
selective breeding from
out bred colony of Long
Evans

Yes

No
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Special model
genetically susceptible
to carbohydrate-rich
diet by selective inbred

(Table 2.3 con’d)
Goto-Kakizaki
Rat(GK)

No

Akita Mouse(non
obese mutant
C57BL/6)

No

Sand Rat

Yes

Develops obesity and
diabetes when in
captivity and fed on
Chow diet (high energy
compared to its low
energy vegetable diet)

C57BL/6J Mouse

Yes

Easy to induce obesity
and diabetes by high fat
diet. This model reflects
both genetic and
environmental
influrences

Acomys Calirinus

Yes

When on high energy
diet and placedcaptivity,
it gains weight and
exhibits impaired
glucose induced insulin
secretion with marked
beta cell hypertrophy.

Diet induced

Chemically
Induced

Polygenic model
obtained from selective
inbreeding of Wistar for
abnormal glucose
tolerance

Alloxan (ALX)

No
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Autosomal dominant
mutation in the insulin II
gene

Induce beta cell necrosis
in rabbits early in
1943.Almost replaced by
STZ due to several
limitations (short halflife; only stable in acid;
variant success rate in
inducing diabetes;

(Table 2.3 con’d)
ketosis and mortality are
high.

Streptozotocin(STZ)

No

Goldthioglucose
Yes
obese diabetic mouse

Partial
pancreatectomy

Surgical models

No

Bilateral Uterine
Artery Ligation

No

Ventromedial
Hypothalamus
Dietary Obese
Diabetic Rat

Yes
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Glucosamine derivative
of nitrosourea. Low dose
multiple injection or in
combination with other
treatments.
Targeted transported to
ventromedial
hypothalamus, cause
necrosis and develop
subsequent hyperphagia
etc. after 16weeks of
injection. High mortality
and long duration limit
its application in
research
70-90 % dissection of
pancreas. Now it is very
useful in pancreatic
regeneration research
Intrauterine growth
retardation induced by
insufficient
uteroplanceta blood flow
leads to hyperglycemia
and impaired beta cell
function in offspring.
Not practical in diabetes
research except for
certain studies.

Induced by high fat high
sucrose diet plus
bilateral electrolyte
lesion of VMH

(Table 2.3 con’d)

Particular model is
generated by altering the
expression of certain
gene or deleting the
endogenous gene in
order to specifically
investigate the role of
the gene in development
of diabetes

Genetically
engineered

2.4.2 Goto-Kakizaki Rat (GK)
The GK rat is a polygenic model of type 2 diabetes derived from Wistar rats in
Japan. Goto and his coworkers performed oral glucose tolerance tests (OGTT) in 211
normal Wistar rats and selected 9 pairs of rats with the highest blood glucose levels as a
foundation breeding stock in the 1970s (Goto et al, 1975). After five generations of
repeated selective breeding for slightly impaired glucose tolerance, a new model of nonobese, non-insulin dependent diabetes was developed. Since the ninth generation, GK rats
began to be inbred to conserve glucose intolerance and impaired glucose-induced insulin
secretion (Galli et al, 1996; Östenson et al, 2001). Up to this date, besides the Japanese
colony, other colonies have been established with breeding pairs from Japan worldwide,
most notably in Paris and Stockholm. Optimal housing conditions with a humidity of
40~60% and temperature of 25~26 oC are essential to breed GK rats (Malaisse-Lagae et
al, 1997).
The GK rat is characterized by moderate hyperglycemia, hypoinsulinemia,
normolipidemia and impaired glucose tolerance which is thought to be the results
primarily of reduced beta cell mass and a defective insulin response to glucose (Portha,
2005; Movassat et al, 1997; Movassat et al, 2007; Movassat et al, 1995). Extensive
38

studies in the Paris GK rats have shown that the beta cell deficit started at fetal age 16
days which led to a more than 50% reduction of beta cells at birth compared with normal
Wistar rats (Miralles et al, 2001). Poor proliferation and enhanced apoptosis of
undifferentiated ductal cells were detected in the GK fetus at embryonic age 16-20 days
and the decreased pool of endocrine precursors was speculated to contribute to the
defective beta cell neogenesis (Miralles et al, 2001; Calderari et al, 2007). In addition,
insulin like growth factor 2 (IGF-2) production was demonstrated crippled and might
account for the retarded beta cell growth (Serradas et al, 2002). Interestingly, maternal
food restriction (65% restriction) during the last week of gestation improved beta-cell
mass and pancreatic IGF-2 levels in GK fetuses, indicating an epigenetic effect
(Fernández-Millán et al, 2009). After birth, GK rats present continuously less beta cell
mass. The total beta-cell mass was only 35% of that in age matched control pancreases
on day 4, 30% on day 7 and 37% on day 14(Movassat et al, 1997). The pancreatic
insulin content was also reduced to as low as 31–40%. Despite this, during this period,
GK neonates exhibited normal basal plasma glucose and glucagon levels until they were
4 weeks old. When the GK rats reach 8 weeks of age, they exhibit marked
hyperglycaemia and slightly low fasting plasma insulin with total beta cell mass reduced
by more than 60% (Movassat et al, 1997).The loss of beta cell mass was ameliorated by
the glycemia lowering drugs glucosidase inhibitor or GLP-1/exendin-4 in adult and
postnatal GK rats (Koyama et al, 2000; Tourrel et al, 2002).
The islet morphology of GK rats is characterized by the presence of ‘starfish
shaped’ islets. In the pancreas of normal Wistar rat, beta cells form a core localized in
the center of the islet whereas non-beta cells envelop a peripheral, continuous mantle.
The boundary is well defined (figure 2.2). In GK rats, the ‘starfish shaped’ islet is
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featured by irregular capsules with disrupted architecture caused by transverse strands of
connective tissue (figure 2.3). The changes in islet morphology are rare in neonatal and
young GK rats, but increase as the animal ages (Suzuki et al, 1992). Several anomalies
were observed existing in the ‘starfish shaped’ islets including inflammatory marker
such as major histocompatibility complex (MHC) II and macrophage-associated
antigens (CD68), overexpression of IGF-2, and these might partially account for the
changes that occurr (Homo-Delarche et al, 2006; Hoog et al, 1996; Hoog et al, 1997).

Figure 2.2 Normal shaped islet (Shafrir, 2007)

Figure 2.3 Starfish shaped islet (Shafrir, 2007)
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The GK rat was generated by selective inbreeding which indicates its hereditary
nature. From cross-breeding studies with GK and Wistar, it suggested that genes from
both parents are necessary for the manifesting of the GK rat to be fully expressed in the
offspring (Serradas et al, 1998).As a polygenetic model of diabetes multiple genes are
involved in the developing of diabetic features in the GK rat. To present, several loci
were found susceptible to glucose intolerance and impaired insulin secretion through
linkage analysis (Galli et al, 1996; Gauguier et al, 1996). Niddm1/Nidd/gk, which resids
on chromosome1, causes defective insulin secretion and is regarded as a main
contributor to postprandial hyperglycemia. Another less important locus
Niddm2/Nidd/gk2 is located on chromosome 2 and influences both fasting and
postprandial glycemia. Weight1.bw/gk1 is on chromosome 7 and is linked to body
weight. Although currently there is no diabetic gene that has been identified in the
aforementioned chromosomal loci, genes coding for mitochondrial glycerol-3-phosphate
dehydrogenase, insulin-degrading enzyme, and uncoupling protein 2 were suggested as
candidates (Fakhrai-rad et al, 2000; Koike et al, 1996; Kaisaki et al, 1998). However, so
far no locus associated with beta cell mass has been found , and the beta cell mass was
reported intact in Niddm1 subcongenics ( Granhall et al, 2006), which raises a question
about whether the genotype alteration is directly linked to low beta cell mass .
There is a growing body of evidence that indicates that impaired beta cell function
is another major pathologic character present in pancreatic islet of GK rats. Compared
with islets form normal Wistar, those from GK rats showed inappropriately reduced
insulin secretion in response to glucose (Mosén et al, 2005; Galli et al, 1996; Mosén et al,
2008). It is generally accepted that glucose induces insulin secretion through following
steps. First, glucose enters the beta cell with aid from transmembrane protein glucose
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transport 2, then produces ATP after a series of reactions (glycolysisand Kreb
cycle).Secondly, the augmented ATP concentration increases the ATP/ADP ratio which
leads to the closure of the ATP-regulated K+ channels. Next the depolarization of the
cell membrane opens voltage-dependent Ltype Ca 2+ channel which causes an influx of
calcium ions. Finally, the elevated cytoplasmic calcium ion promotes exocytosis of
insulin granules. Any defects in this pathway will result in the diminished insulin
secretion response to glucose. Glucose transport 2 was found underexpressed in GK rats,
but this is unlikely to be the only causal factor (Ohneda et al, 1993). Several defects in
the main enzymes that catalyzed oxidative glycolysis have been reported which
consisted of reduced activity of FAD linked glycerol phosphate dehydrogenase
(Fabregat et al, 1996), pyruvate dehydrogenase (Zhou et al, 1995), and pyruvate
carboxylase (MacDonald et al, 1996). However, the decreased enzyme activity was
restored when glucose was normalized by insulin (MacDonald et al, 1996). In addition,
over expression of FAD linked glycerol phosphate dehydrogenase in GK rats didn’t
correct altered insulin secretion (Ueda et al, 1998). Other possible mechanisms are
suggested such as dysfunction of lysosomal glycogenolytic enzymes (Salehi et al,1999),
anomaly of glucose-heme oxygenase-carbon monoxide signaling pathway (Mosén et al,
2005), reduced NADH/NAD ratio by enhanced activity of adenylyl cyclase III (AbdelHalim et al, 1993) which further studies are needed to verify.
Arginine, a nonglucose insulin secretagogue, was shown to induce an increased
pancreatic insulin response in GK rat (Hughes et al, 1994; Abdel-Halim et al, 1993).
However, Portha and his co-workers reported that in the absence of glucose arginine
failed to induce a normal insulin response in GK rats as it did in the control rats (Portha
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et al, 1991).Therefore, arginine stimulated insulin secretion might also be disturbed in
GK rats.
It has been proposed that the reduced beta-cell mass and impaired function in the
GK model are ascribed to an interaction of multiple pathogenic factors: (i) defects in
several genes account for weakened insulin secretion; (ii) decreased beta-cell neogenesis
and/or proliferation due to an epigenetic influence of gestational metabolic programming
in the pancreas; and (iii) secondary loss of beta-cell differentiation due to chronic
exposure to hyperglycemia (Portha et al, 2009; Portha, 2005).
Insulin sensitivity in GK rat has been studied using the hyperinsulinemiceuglycemic clamp in vivo and in tissues such as liver, muscle and adipose tissue in vitro.
Suzuki et al. utilized the clamp in combination with a tracer to show that the
disregulation of hepatic fructose-2,6-bisphosphate and subsequent elevation of hepatic
glucose production was the main reason for mild insulin resistance in GK rats (Suzuki et
al, 1992). Other defects featured by a decrease of receptor number with normal tyrosine
kinase activity and attenuated inhibition of insulin on glucagon-induced hepatic glucose
production were also observed (Doi et al, 2001). In skeletal muscle, the blunted
conversion of glucose to glycogen due to chronic activation of protein kinase C was
regarded as one of the contributors to insulin resistance (Avignon et al, 1996). In
addition, several defects in the postreceptor insulin signaling pathway were
demonstrated in adipose tissue and skeletal muscle that included the impaired insulin –
stimulated tyrosine phosphorylation of insulin recptor substrate-1 (Begum et al, 1998),
and attenuated PI3K activated Akt kinase (Krook et al, 1997). Interestingly, the Akt
kinase acvitity was able to be restored after nearly normalization of glycemia in GK rats,
which suggested that the impaired insulin sensitivity in extrahepatic tissues is probably
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secondary to hyperglycemia (Krook et al, 1997). These observations as well as the
pathological progress in insulin-mediated muscle glucose transport with aging indicate
the supporting role of insulin resistance and the leading effect of a beta-cell secretory
defect in the development of diabetes in the GK rats.
2.5 Methods of Measuring Insulin Sensitivity
Systemic (whole body) insulin resistance is determined by insulin sensitivity in
the insulin target tissues, which include muscle, heart, liver, and fat. Muscle insulin
resistance is a major portion of systemic insulin resistance. Several factors are known to
induce insulin resistance. These include obesity, lipodystrophy, genetic background,
inflammation, free fatty acids/intermediates, ectopic fat in muscle, endoplasmic reticulum
stress, oxidative stress, hyperinsulinemia, mitochondrial dysfunction and aging.
The insulin resistance can be measured with a combination of markers that
represent characteristics of insulin resistance. These include hyperinsulinemia, decreased
glucose infusion rate, hyperglycemia, impaired glucose tolerance and so on.

.

2.5.1 Direct Measures
2.5.1.1 Euglycemic Hyperinsulinemic Clamp
The euglycemic hyperinsulinemic clamp is regarded as the "gold standard" for
measuring whole body insulin sensitivity (Muniyappa et al, 2008). It directly measures
glucose utilization promoted by insulin in the steady state. In this method, insulin is
infused at a constant rate after an overnight fast to raise blood insulin concentration to
certain level that is higher than that in the fasting phase, which is the origin of
‘hyperinsulinemia’. This hyperinsulinemia results in suppression of hepatic glucose
production and increase of glucose disposal in skeletal muscle and adipose tissue. In the
meanwhile, 20% dextrose is administered intravenously to maintain euglycemia which is
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monitored by frequently using glucose analyzed every 5 to10 minutes. Considering that
there is no net glucose change in the steady state given that the hyperinsulinemia can
suppress hepatic glucose production completely, the glucose infusion rate (GIR) that is
needed to maintain euglycemia status would be equal to the glucose disposal rate.
However, the clamp method is based on assumptions: 1.hyperinsulinemia suppresses
hepatic glucose production entirely; 2.a steady state condition is achieved at the end of
the procedure; 3. insulin infusion rate is properly chosen for the target population in
terms of insulin sensitivity. GIR is usually needed to be normalized for fat-free mass.
Sometimes GIR is adjusted for the blood glucose concentration in the steady state
condition, and the difference in insulin concentration between the fasting stage and the
steady state condition where is formulated as GIR/ (G ×ΔI). This is the insulin index
derived from clamp.
The clamp requires blood sample collection, and the procedure per se is very
complicated and time consuming, which limits its application in large-scale human and
animal studies.
2.5.1.2 Insulin-suppression Test (IST)
The insulin-suppression test is another method besides the clamp that directly
measures metabolic insulin sensitivity/resistance. It measures the ability of exogenous
insulin to drive glucose utilization in peripheral tissues under steady-state circumstance
provided with complete inhibition of endogenous insulin secretion (Harano et al, 1978).
In this procedure, patients fasted overnight receive i.v. somatostatin at a constant rate
(250 μg/h) or the somatostatin analogue octreotide (25 μg bolus, followed by 0.5 μg/min)
to achieve a full suppression of endogenous secretion of insulin and glucagon.
Simultaneously, sustained infusions of exogenous insulin (25 mU/m2/min) and glucose
45

(240 mg/m2/min) into the same antecubital vein over 3 h are performed to obtain steady
states of plasma insulin and plasma glucose. Blood samples from the other forearm are
collected every 30 minutes for the first 150 minutes and then every 10 minutes for a half
an hour after initiation of the infusions. The second period is usually considered as the
steady –state phase. The steady-state plasma glucose (SSPG) concentration and steadystate plasma insulin (SSPI) concentration are determined at this stage. Considering that
the universal insulin infusion rate for all subjects would result in generally similar SSPIs,
insulin sensitivity is inversely related to the SSPG values. The formula calculated in IST
is ISI (dl · kg–1 · min–1) = [glucose infusion rate (mg kg–1 · min–1)/SSPG (mg/dl)] ×
103. Similar as the clamp, IST is based on several assumptions: 1. somatostatin infusion
is sufficient to suppress endogenous secretion of insulin and glucagon; and 2.hepatic
glucose production is completely inhibited. Although IST has its advantages over clamp
such as it is easier to achieve a steady-state condition, less labor intensive, it is still not
practical in the clinical care setting and large studies. And some errors may be introduced
in cases like type 2 diabetics and extremely insulin sensitivity individuals.
In addition to the aforementioned direct measures of insulin sensitivity, two
indirect measures are presented below.
2.5.2 Indirect Measures
2.5.2.1 Minimal Model
Minimal model is a mathematical model with 2 coupled differential equations
and 4 parameters. The first equation represents plasma glucose dynamics and the second
equation describes insulin dynamics in two separated compartments.
It allows calculating insulin sensitivity in a dynamic state on the basis of
concentrations of glucose and insulin collected from a “frequently sampled intravenous
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glucose tolerance test” (FSIVGTT). During this 3-hour procedure, a bolus of glucose
(0.3g/kg body weight) is administered intravenously over 2 minutes in an overnight
fasted patient at time 0. Blood samples are collected for plasma insulin and glucose
which are used to generate the index of insulin sensitivity (SI) and glucose effectiveness
(SG) and obtain information about β-cell function (Bergman et al, 2002). SI is defined as
fractional glucose disappearance per plasma insulin unit, and SG is the ability of glucose
to inhibit hepatic glucose production and mediate glucose disposal independent of
increased insulin. In humans, the peak insulin induced by FSIVGTT overlaps the glucose
effectiveness period, as well as the inadequate endogenous insulin secretion in diabetics,
a modified FSIVGTT was developed with infusion of exogenous insulin or tolbutamide
over 5 minutes at 20 minutes after the glucose bolus (Quon et al, 1994; Saad et al, 1997).
This minimal model analysis has been demonstrated to be comparable to the
clamp in healthy subjects (Beard et al, 2007), and has been used in relative large scale
study (Howard et al, 1996). However, it lumps together insulin’s ability of suppressing
hepatic glucose production and accelerating glucose disposal, so it is less accurate in
insulin resistant subjects.
2.5.2.2 Oral Glucose Tolerance Test/Meal Tolerance Test
Being abbreviated as OGTT/MTT, it is a dynamic test to measure glucose
intolerance and obtain indirect information of insulin sensitivity when combined with
other assay. The procedure is much simpler and is widely applied in the clinical setting to
diagnose type 2 diabetes (ADA, 2007) After an overnight fast, blood is drawn for glucose
and insulin at 0, 30, 60, and 120 minutes preceded by an oral 75 gram glucose load or
standard meal. It is important to note that, glucose tolerance is a comprehensive outcome
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involving insulin secretion, other hormones, and insulin sensitivity. It is not equivalent to
insulin sensitivity.
Simple surrogate measures of insulin sensitivity have been proposed and assessed
against the clamp.
2.5.3 Surrogate Indexes from Fasting Steady State
2.5.3.1 HOMA Model
The homeostatic model assessment (HOMA) uses a set of empirically derived
nonlinear equations to estimate insulin resistance and beta-cell function from fasting
glucose and insulin data. The approximation equation yielded from this model to
determine index of insulin sensitivity is HOMA-IR: Glucose (mmol/l) x Insulin (µU/mL)
/22.5. The result calculated from this equation has a good linear correlation with results
from the euglycemic clamp method (Radziuk, 2000)
2.5.3.2 Quantitative Insulin Sensitivity Check Index (QUICKI)
QUICKI is another mathematical equation used to estimate insulin sensitivity
based on a log transform of the product of the fasting blood glucose and plasma insulin
concentrations. It was developed upon the discovery that the data from the first 20
minutes of an FSIVGTT was adequate to generate a reliable index for insulin sensitivity
as that determined by a reference glucose clamp (Katz et al, 2000). Additional log
transformation was taken to maintain linear correlation with the clamp in diabetics.
QUICKI showed better linear correlation with the clamp than the HOMA and minimal
model methods (Cobelli et al, 1998; Katz et al, 2000). QUICKI, as a simple, accurate
index of insulin sensitivity as well as one of the most thoroughly evaluated is appropriate
for large scale studies.
QUICKI=1/[log(fasting insulin, u U/ml)+log( fasting glucose, mg/dl)]
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2.5.4 Surrogate Indexes from Dynamic Test
Based on glucose and insulin data from OGTT, IVGTT, MTT, or OGTT/MTT
combined minimal model, a number of indexes have been developed, such as the Insulin
sensitivity index-Matsuda, Avignon index, oral glucose insulin sensitivity index, and Gutt
index. Many of these indexes correlate well with the glucose clamp estimates of SI (Gutt
et al , 2008; Mari et al, 2001; Matsuda et al, 1999). The advantage of the dynamic test
based surrogates is to be able to get both data about insulin secretion and insulin action at
same time. However, the decision of choosing fasting surrogates or dynamic surrogates
depends on research interest.
ISI(Matsuda) = 10,000/ [(Gfasting x Ifasting) x (GOGTTmean x IOGTTmean)]
Gutt index= MCR/log MSI = m/MPG/log MSI. The glucose uptake rate in
peripheral tissues m = [75,000 mg + (Glucose0 – Glucose120) x 0.19 x BW]/120 min,
The metabolic clearance rate (MCR) = m/MPG (mean of the glucose concentration at 0
and 120-min of the OGTT). MSI stands for mean serum insulin (mU/l) is the mean
plasma insulin concentrations at 0- and 120-min of the OGTT.
2.5.5 Measures in Animal
As in human, the euglycemic-hyperinsulinemic clamp is also the ‘gold standard’
for measuring whole body insulin sensitivity in animals. However, especially in rodents,
due to the lack of true physiologic fasting state and a small blood volume, the clamp is
not easy to conduct. Intraperitoneal glucose tolerance test (IPGTT) and insulin tolerance
test (ITT) are two frequently used methods of measuring glucose tolerance and insulin
sensitivity in rodents (Gao et al, 2009). Although they can’t estimate insulin sensitivity as
precisely as the clamp does, they are still the method of choice when insulin sensitivity is
of secondary interest or the clamp is infeasible.
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In animals, HOMR-IR and QUICKI also have been validated by examining
correlations with the reference glucose clamp method (Cacho et al, 2008; Lee et al, 2008).
The equation is HOMA-IR: Glucose (mg/dl) x Insulin (µU/mL) /2430. Overall, these two
surrogates provide a reliable and simple estimate of formal measures of insulin sensitivity
with variability and discriminant power comparable to the clamp when applied to rats and
mice (Cacho et al, 2008).
2.6 Adiponectin
Aiponectin is a 244- amino acid protein encoded by gene located on chromosome
3q26 (Ruan et al, 2003). It is produced mainly by white adipose tissue, tracely by brown
adipose tissue, liver, muscle etc. (Vienngchareun et al, 2002). Adiponectin is the most
abundant adipose tissue derived hormone and the average plasma concentration in
humans ranges from 5~30 ug/ml, about 1000 times more than leptin (Berg et al, 2002). In
the circulation adiponectin exists in multimers, high-molecular-weight isoform, mediummolecular-weight hexamers, and low-molecular-weight trimers, among which the highmolecular-weight is proposed to be more biologically active than other forms
(Heidemann et al, 2008; Lara-Castro et al, 2006). Adiponectin has a profound insulin
sensitizing effect as well as anti-inflammatory and antiatherogenic effects. It also
promotes food intake as the result of action in the hypothalamus (Kubota et al, 2007).
The plasma adiponectin level is found negatively correlated with visceral adiposity,
insulin resistance, type 2 diabetes, and cardiovascular disease (Aso et al, 2006; Li et al,
2009). However, in the growing stage, adiponectin is initially increased with the
accumulation of adiposity and then begins to decrease as the mice reach adulthood
(Ziemke et al, 2010). A diet rich in whole grain, consumption of nuts, coffee and
moderate alcohol ( Mantzoros et al, 2006), peroxisome proliferator-activated receptor
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agonist (Combs et al, 2002; Tonelli et al, 2004) and physical training (Bluher et al,
2006;Bluher et al, 2007) are shown to be associated with an increase of plasma
adiponectin concentrations.
Two 7-transmembrane proteins with external C terminal and internal N terminal
regions have been identified as receptors for adiponectin (Yamauchi et al, 2003).
Although both receptors are globally present, Adipo R1is highly expressed in muscle
while Adipo R2 is dominant in the liver. AdipoR1 knockout mice exhibit increased
adiposity, decreased glucose tolerance, physical activity, and energy expenditure. On the
contrary, AdipoR2 deficiency resulted in increased physical activity and energy
expenditure, lowered plasma cholesterol levels, and an enlarged brain size. These mice
are resistant to HFD-induced obesity and glucose intolerance (Bjursell et al, 2007). The
adiponectin concentration in the blood stream is in proportion to the expression of Adipo
R2 in subcutaneous fat whereas it is negatively related to the expression of Adipo R1/R2
in muscle; however, in insulin resistance the expression of the receptors in both location
was increased (Bluher et al, 2006; Bluher et al, 2007).
Adiponectin mainly signals through AMP-activated protein kinase to exert its
beneficial effects on the above mentioned diseases after binding to the receptors
(Yamauchi et al, 2002). Several other signaling pathways are also proposed as mediators.
Pathways involved include mTOR, nuclear transcription factor-kB, STAT3, and JNK
(Averous et al 2006; Miyazaki et al, 2005; Tomas et al, 2002).
Accumulating evidence supports linkage between altered circulating adiponectin
and insulin resistance /type 2 diabetes. Lower plasma total adiponectin was not only
shown associated with increased insulin resistance (Stefan et al, 2002), but also was
found in type 2 diabeteics compared with BMI- matched controls (Hotta, et al, 2000). In a
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meta-analysis including thirteen prospective studies with a total of 14 598 subjects and
2623 type 2 diabetics, it was observed that adiponectin levels were inversely associated
with the risk of developing type 2 diabetes. The relative risk of type 2 diabetes for each
one unit increment of adiponectin was 0.72 indicating a protective role of adiponectin in
the occurrence of type 2 diabetes (Li et al, 2009). Animal studies also were in accordance
with observations in humans. Adiponectin knockout mice showed notable insulin
resistance on a high fat, high sucrose diet; a supplement of adiponectin improved this
insulin resistance (Maeda et al, 2002). A similar insulin resistance reversal effect was
reported when physiologic doses of adiponectin were replenished to a lipoatrophic mouse
model (Yamauchi et al, 2001).
In most epidemiological studies it is the total immunoreactive adiponectin that was
assessed rather than the multimeric forms of adiponectin. One study reported that
although the total adiponectin was significantly related to glucose intolerance, the ratio of
high molecular weight to total was a tighter indicator in Indo-Asian males (Fisher et al,
2005). However, contradictory results have shown that total adiponectin was not
correlated with insulin sensitivity whereas the ratio of high molecular weight to total was
positively correlated (Pajvani et al, 2004). Lara-Castro et al found total adiponectin, high
molecular weight, low molecular weight, and high to total ratio were all significantly
associated with the insulin stimulated glucose disposal rate. Moreover, all these
indicators were positively correlated with reduced central fat distribution and augmented
fat oxidation rate. Regarding the lipoprotein profile, high molecular weight and total were
related to favorable changes. After further analyisis, the authors concluded the quantity of
high molecular weight was the primary factor for all these relationships (Lara-Castro et al,
2006).
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Maternal circulating adiponectin was also found lower in pregnant women with
gestational diabetes (Csehet al, 2004; Ranheim et al, 2004; Kinalski et al, 2005; Ategbo
et al, 2006;). Low plasma adiponectin is also proposed as a risk factor for gestational
diabetes. Women with adiponectin concentrations less than 6.4 ug/ml at the 13th week of
gestation had a 4.6-fold increased risk of developing gestational diabetes in later
pregnancy (Williams et al, 2004). A recently published study explored the distribution of
adiponectin multimers in gestational diabetes patients (Mazaki-Tovi et al, 2009). The
results revealed that maternal serum of total, high, medium, low, and high/total were
decreased in pregnant women with GDM compared to weight matched normal pregnant
controls. Furthermore, all multimers were not different between obese/overweight GDM
patients and normal weight GDM patients, albeit the former usually have lower
concentrations than the latter without the presence of GDM. In addition, interventions
such as insulin and glyburide displayed no impact on the concentrations and relative
distribution of adiponectin multimers.
Patients with coronary heart disease had lower plasma adiponetin levels than age
and BMI matched controls (Ouchi et al, 1999). In a case control study conducted in male
patients, it was shown that an adiponectin concentration less than 4ug/ml was related to a
2 fold increase of incidences of coronary heart disease and it was independent of other
risk factors (Kumada et al, 2003). Additionally, high adiponectin levels were indicated as
having an inverse association with occurrences of acute myocardial infarction in men
(Pischon et al, 2004). In cardiac hypertrophy caused by pressure overload in three types
of mice, adiponectin-deficient, wild-type and diabetic db/db mice, a supplement of
adiponectin conveyed by adenovirus attenuated the severity of the condition, and the
inactivation of AMPK blunted these effects (Shibata et al, 2004). Furthermore,
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adiponectin prevented plaque rapture by increasing both RNA and protein expressions of
tissues inhibitor of metalloproteinase in macrophages through the promotion of interlukin
-10 synthesis. Tissue inhibitor metalloproteinase can stabilize plaque by suppressing
matrix metalloproteinase (Kumada et al, 2004). Adiponectin also inhibited vascular cell
adhesion molecule1and intracellular adhesion molecule1, thereby prevented monocytes
from binding to vascular endothelial cells (Ouchi et al, 2000). Besides, adiponectin
suppressed smooth muscle cell migration and proliferation in vascular remodeling by
inhibiting mitogen activated protein kinase (Arita et al, 2002). Adiponectin shows
protective features on cardiovascular disease as positively correlated with favorable lipid
profile (high HDL and low apoB100, triglycerides) (Schulze et al, 2005) and facilitating
endothelial nitric oxide synthesis (Chen et al, 2003).
2.7 Physiological Role of UCP-1
2.7.1 Coupling and Uncoupling
The mitochondrion is a membrane-enclosed organelle in most eukaryotic cells
(Henze et al, 2003). It is composed of compartments which include an outer membrane,
inner membrane, intermembrane space, cristae and matrix. The small molecules such as
glucose and ions are able to permeate the outer membrane freely. However, the inner
membrane is nearly impermeable to all molecules since it does not contain porins
(Herrmann et al, 2000). The notable membrane potential across inner membrane is
established by the electron transport chain.
Electron transport chain is located in the inner membrane. It contains Complex I, II,
III and IV. In Complex I (NADH dehydrogenase or NADH: ubiquinone oxidoreductase),
two electrons are delivered from NADH to ubiquinone (Q) which is a lipid-soluble
carrier and can diffuse freely in the membrane. Simultaneously, Complex I translocates
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four protons from matrix to intermembrane space across the inner membrane. Complex II
(Succinate dehydrogenase or succinate-coenzyme Q reductase) is involved in both citric
acid cycle and the electron transport chain (Oyedotun et al, 2004). It catalyzes succinate
oxidation to fumarate. The electrons derived from succinate oxidation were transferred to
an ubiquinone, which reduces the ubiquinone to an ubiquinol (QH2). Complex III
(coenzyme Q : cytochrome c — oxidoreductase or cytochrome bc1 complex) delivers
two electrons from QH2 to cytochrome C. Concomitantly, four protons are pumped from
the mitochondrial matrix into the intermembrane space ( Crofts et al, 2004;Kramer et
al,2004). Complex IV (cytochrome c oxidase) transfers four electrons from four
molecules of cytochrome c to oxygen and produces two molecules of H2O.
Simultaneously, four protons are pumped across inner membrane to intermembrane space.
With continuously pumping protons from the matrix to the intermembrance space
by complex I, III and IV, a proton gradient or membrane potential cross the inner
membrane is formed. This gradient is used by ATP synthase, which also locates in the
inner membrane, to produce ATP through oxidative phosphorylation. Accumulated
protons in the intermembrance space return to the matrix through ATP synthase which
acts similar to an ion channel. Free energy released by the proton reflux fuels the ATP
synthesis ( Boyer et al, 1997; Yoshida etal, 2001). During the process, the electron
transport chain is coupling with oxidative phosphorylation via its formed proton gradient.
In addition to ATP synthase, accumulated protons in the intermembrane space are
able to return to the matrix through some other ion channels such as uncoupling protein1
(UCP-1) ( Kozak et al, 1998; Nicholls et al, 1978). The uncoupling process produces lots
of heat instead of ATP like like a short circuit.
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2.7.2 Thermogenesis of UCP-1
UCP-1 (Thermogenin) is highly present in brown adipose tissue which is only
found in mammals. The main activity of UCP-1 is to generate heat via non-shivering
thermogenesis, which plays an important role in heat generation of hibernating and
newborn mammals (Rial et al, 2009). The mitochondrial proton circuit caused by UCP-1
leads to fast substrate oxidation without ATP production. Fatty acids are the major
messengers to activate UCP-1, which is inhibited by purine nucleotides.
Brown adipose tissue (BAT) is scattered in the body such as interscapular,
surrounding the kidneys and aorta (Mattson et al, 2010). The heat generated by UCP-1 is
transferred to the body easily since BAT is much vascularized (Smith et al,1964). Cold
exposure is able to increase vascularization of BAT via stimulating angiogenesis (Asano
et al,1999). That will increase the heat diffused through the body.
2.7.3 UCP-1 and Diabetes
Diabetic rats induced by alloxan injection had significantly decreased UCP-1
expression (Vasilijevic et al, 2010). A leucine-deficient diet reduced abdominal fat mass
in mice. That may be mediated by induced expression of UCP-1 in BAT (Cheng et al,
2010). IKKepsilon knockout mice are protected from high-fat diet-induced obesity and
whole-body insulin resistance. These mice show increased energy expenditure and
thermogenesis via enhanced expression of the UCP-1 (Chiang et al, 2009).
Recently, substantial depots of BAT were identified in a region extending from the
anterior neck to the thorax (Cypess et al, 2009). UCP-1 was detected in the BAT. The
amount of BAT is inversely correlated with body-mass index, especially in older people,
and age, indicating a potential role of brown adipose tissue in the adult human
metabolism.
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2.8 Gut Microbiota and Metabolism
2.8.1 Normal Human Gut Microbiota
The human gastro-intestinal tract contains numerous microorganisms, known as
‘microbiota’, of which bacteria are the most dominant and largely diverse. The gastrointestinal tract flora is essential in maintaining normal gut function and host’s health,
such as forming a physical barrier which is critical in the development of mucosal and
systemic immune systems and salvaging energy from dietary compound escaping
digestion in the upper gastro-intestinal tract. Studies using germ free mice have shown a
lack of gut microbiota made the animal more susceptible to infection, to having reduced
digestive enzyme activity, and have less serum immunoglobulin levels (Shanahan et al,
2002). However, the digestive system microbiota also consists of potentially pathogenic
bacteria.
The composition of the gut microbiota is so complicated and individualized that
our understanding was largely limited by technical issues until the 16S ribosomal RNA
gene based approaches facilitated the process. There is a growing body of evidence that
the indigenous gut microbiota is established during the first year of life (Xu et al, 2003;
Gronlund et al, 1999; Favier et al, 2002; Midtvedt et al, 1992). In the uterus the gastrointestinal system of a fetus is germ free. At birth as the infant is exposed to the bacteria
from the mother’s vagina, feces, skin and the environment, the intestinal colonization
commences and progresses dramatically from sterility to broad mixtures of microbes
(Edwards et al, 2002; Xu et al, 2003). The colonization is influenced by several factors,
such as the mode of delivery, diet and environmental hygiene level (Gronlund et al, 1999).
Cesarean infants have a delayed colonization with Bifidobacterium spp and Lactobacilli
spp up to 30 days whereas vaginally delivered infants normally start colonization with
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Bifidobacterium spp 3-4 days after birth (Kurokawa et al, 2007). Moreover, cesarean
infants have a reduced number of bacteria compared with naturally delivered infants
(Morelli, 2008). Bifidobacterium spp and Enterobacteriaceae are two early colonizers.
Breast-fed infant digestive tracts are dominated with Bifidobacterium spp, whereas
Enterobacteriaceae is prominent in formula-fed infant digestive tracts along with
Bacteroides spp and the Clostridia spp family (Tannock et al., 1990; Mountzouris et al,
2002). Besides, the addition of solid food to the breast-fed infant caused a significant
change in composition of the gut flora; however, it didn’t have the same impact in the
formula-fed infant (Stark et al, 1982). Gestational age is another factor influencing
colonization. Studies show premature infants underwent delayed colonization with more
virulent species (Kosloske et al, 1994; Orrhage et al, 1999).
During the weaning stage and thereafter, intestinal microflora changes rapidly and
it takes up to 24 more months for the gut microbiota to complete the transformation to
adult-type with unique and diverse groups of flora (Zoetendal et al, 1998). After the
adult-type microbiota is formed, it remains quite constant during a considerable period of
lifespan (up to 7th decade), with some fluctuation around the core colonies (Ley et al,
2006). Upon aging, the composition begins to change with a dramatic decrease of
protective bacteria i.e. Bifidobacterial species and increase of enterobacteria which are
considered detrimental bacteria (Mitsuoka et al, 1982; Hopkins et al, 2001). The ratio of
Firmicutes/Bacteroidetes was also reported increased with age as well as the Bacteroides
species richness; despite the age-related reduction in the Bacteroides number (Mariat et al,
2009).
In the adult, the microbial community residing in the human body outnumbers
total host cells by ten-fold, and consists of at least 1014 bacteria which belong to up to
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1000 different species(Cani et al, 2007). The microbiome is about 100 times more than
the human genome (Kurokawa et al, 2007). Although the microbiota in the gastrointestinal tract has large variability between individuals (Eckburg et al, 2005), the
predominant bacteria divisions are relatively constant, and the majority of the bacterial
population (>90%) is anaerobes. The dominant bacterial phyla are Firmicutes,
Bacteroidetes and Actinobacteria (Backhed et al, 2005). Firmicutes contains over 200
genera. It is the largest bacterial phylum in the adult human gastro-intestinal tract.
Species belonging to this phylum include Lactobacillus, Mycoplasma, Bacillus,
Eubacterium and Clostridium (Zoetendal et al, 2006; Backhed et al, 2005). The
Bacteroidetes includes about 20 genera among which Bacteroides is potent for digesting
otherwise indigestible dietary polysaccharides in the distal intestinal habitat of adult
humans (Xu et al, 2003). Actinobacteria and Firmicutes are gram-positive whereas
Bacteroidetes is gram-negative; fluorescent in situ hybridization (FISH) rather than RNA
gene sequencing is currently the only technique to detect Actinobacteria (Zoetendal et al,
2006).
As mentioned above, the gut microflora differs remarkably from one person to
another. Among multiple host and external factors which influence the composition of
the core microbiota, genetic makeup is the most important determinant. Studies
demonstrated that identical twins have greater similarity of gut microbiota than those of
unrelated individuals, even though the twins live separately (Turmbaugh et al, 2009). To
the opposite, biologically unrelated people who spent life together for a long time didn’t
show a significant resemblance in the composition of gut bacterial communities
(Zoetendal et al, 2001).
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The distribution of the bacterial population is uneven in different parts of the
gastro-intestinal tract. The large intestine has the largest number of bacteria with an
average of 1011-1012, and most of them are anaerobes from three prominent divisions in
human gut. The mouth contains around 1010 microflora with more than 500 bacterial
species and is the habitat of the second largest population of bacteria (TlaskalovaHogenova et al, 2004). Most of the bacterial species are hindered by the acid digestive
fluid and pancreatic secretions in the stomach and proximal intestine. There are about
101-103 bacteria present in the stomach among which the most common microbe is
Gram negative Helicobacter pylori(Tlaskalova-Hogenova et al, 2004).

Figure 2.4 The phylogenetic tree of the most frequently detected phylotypes in human
faeces using 16S rRNA gene sequencing (Vrieze et al, 2010)
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It is an opportunistic pathogen and regarded as a contributor to gastric ulcers and
gastric cancers. Although the small intestine harbors 104-107 bacteria, which the majority
is Firmicutes such as Lactobacilli, Bacilli and Gram positive Coci, it is usually
considered ‘relativly sterile’ due to a number of nonimmune and immune factors such as
pancreatic juice, constant movement, and secretory immunoglobulin A (Kleinman et al,
2008). Figure 2.5 visualized the distribution of bacteria in various parts of the gut.
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Coci

Colon
Bacteroides
Bifi dobacterium
Eubacterium
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Figure 2.5 Distribution of microflora in gut (adapt from Tsukumo et al, 2009)
2. 8. 2 Gut Microbiota and Energy Metabolism
Type 2 diabetes and Obesity are two metabolic diseases that are becoming
epidemics not only in developed western countries but also in developing countries.
Obesity per se is shown to be a causal factor for type 2 diabetes that is evidenced by
interventional weight reduction and decrease of diabetes incidence in multiple studies
(Laville et al, 2009; Horton et al, 2010; Fujioka et al, 2010). Numerous studies have shed
light on the combination of variable environmental and genetic factors as causal factors
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in the development of these two metabolic diseases. Excessive energy intakes as well as
decreases of physical activity are two common external factors. However, within families,
some individuals are more prone to have diet-induced weight gain and hyperglycemia,
even though they were exposed to similar nutritional circumstances (Turmbaugh et al,
2009; Hill et al, 1998; Christakis et al, 2007; Tappy et al, 2007). Such observations
suggested apart from traditional triggers, other novel factors also are involved. Over the
last several years, there is growing evidence of gut microbiota as a potential
environmental factor in the control of energy homeostasis (Ley et al, 2005; Ley et al,
2006; Turnbaugh et al, 2006; Backhed et al, 2007).
2.8.2.1. Evidence of Association between Gut Microbiota and Metabolic Diseases
A number of studies have revealed the composition of gut microflora changes in
obesity and diabetes. Larsen et al reported the proportion of Firmicutes was significantly
lower in diabetics compared to the control group and the reduction in Clostridium ssp
was the main reason for the decrease. Although, phyla Bacteroidetes and Proteobacteria
were not observed significantly enriched in the diabetic group, the authors found a
positive correlation between the ratio of Bacteroidetes to Firmicutes and blood glucose
(Larsen et al, 2010). Ley and coworkers analyzed 5,088 bacterial gene sequences and
found variation in gut microbita between obese and lean mice. Obese mice demonstrated
a reduction in Bacteroidetes at 50% and proportional elevation in Firmicutes compared
with lean mice (Ley et al, 2005). Similar findings observed in human, obese people tend
to have fewer Bacteroidetes and more Firmicutes than lean people. Moreover, loss of
weight after being on a hypocaloric diet resulted in the reversal of microflora in obese to
that observed in lean (Ley et al, 2006; Tumbaugh et al, 2008). Interestingly, it was the
number of Bateroidetes not energy intake that correlated with weight loss (Nadal et al,
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2008). However, not all studies supported the ‘high Firmicutes/low Bacteroidetes’
hypothesis (Zhang et al, 2009; Duncan et al, 2008). Duncan et al reported no difference in
Firmicutes to Bacteroidetes ratio between obese and lean subjects, neither significant
relationships existing between the ratio and BMI. Schwiertz and co-workers presented
similar results. They suggested that the amount of SCFA produced might be important
rather than the ratio of bacteria (Schwiertz et al, 2010).

Figure 2.6 Proportion of Firmicutes and Bcteroidetes in lean and obese (Tsukumo et al,
2009)
Studies of germ-free mice and microbiota transplantation further demonstrated
how gut microbiota affects the energy metabolism. Gordon’s group found that germ-free
mice had higher energy intake but exhibited 40% lower body weight, 42% less total body
fat and a 47% reduction of gonadal fat compared with conventional mice with the same
age and genetic background. Interestingly, after colonized with gut microflora from
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conventional mice, the germ-free mice gained 60% in body fat along with increased
insulin resistance within 2 weeks (Backhed et al, 2004). To test whether microflora
profile is critical in the fat gain, the germ-free mice were transplanted with gut microflora
from ob/ob mice and lean mice, respectively. They showed that the microbiota from
ob/ob mice resulted in a greater fat gain than that from lean mice. They also confirmed
that ob/ob microbiota recipients had higher relative abundance of firmicute than lean
microbiota recipients (Tumbaugh et al, 2006).
2.8.2.2. Mechanisms underlying the Association between Gut Microbiota and
Metabolic Diseases
•

Energy Harvesting Theory
One of the biological functions of microflora is to digest otherwise indigestible

dietary compound (polysaccharides), thereby they provide extra energy to the host. The
different composition of microflora observed in lean and obese provoked a hypothesis
that the gut bacteria from obese may be more efficient in extracting additional energy
from the diet. Backhed and colleagues showed that the microbiota of obese mice had
more gene encoding enzymes for breaking down polysaccharides and underwent more
fermentation. There were fewer calories left in the feces of obese mice (Backhed et al,
2004). However, it still remains unclear if such a small amount of additional energy
extraction could lead to a sufficient weight gain within a short period of time. Besides,
non-digestible fiber has been reported to decrease body weight, reduce body fat and
improve diabetes (Cani et al, 2006; Shen et al, 2009). Therefore, this observation is not in
accordance with the hypothesis of “increased energy harvesting by bacteria” contributing
to obesity.
•

Induction of Low Grade Inflammation
Obesity and type 2 diabetes are characterized by a low grade inflammation
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(Wallen et al, 2005). A recent study showed toll like receptor 4 was involved in the
inflammation response triggered by fatty acid following a high fat diet. A high fat diet
failed to induce inflammation in toll like receptor 4 knockout mice (Shi et al, 2006). Cani
and colleagues found toll like receptor 4 was a coreceptor for lipopolysaccharides (LPS)
and LPS was a potent inducer of inflammation derived from breaking down of gram
negative bacteria in gut (Cani et al, 2007b). Therefore, they proposed that LPS is a gut
microbiota related triggering factor for inflammation. They demonstrated that continuous
low rate infusion of LPS caused weight gain and insulin resistance. The CD14 knockout
mice, lacking the LPS receptor, did not exhibit the same changes (Cani et al, 2007a).
CD14, is a glycosylphosphatidylinositol (GPI)-anchored protein expressed by
macrophages (MΦ) and neutrophils, involved in production of proinflammatory
cytokines in response to bacterial lysate or purified agonists such as LPS (Sahay et al,
2009). They also reported that a high fat diet led to a reduction of bifidobacteria, an
increase of gram negative to gram positive ratio which was associated with a significant
elevation of LPS in plasma, blunted insulin sensitivity and diabetes (Cani et al, 2007b).
LPS was found higher in type 2 diabetes patients than age matched non-diabetics (Creely
et al, 2007). Several studies have indicated that modulation of the gut bacterial population
could be effective in improving glycemic control and insulin sensitivity. Using gram
negative targeted antibiotics such as norfloxacin and ampicillin improved whole body
glucose tolerance and reduced hepatic steatosis/ fatty liver diseases through modification
of gut microbiota (Membrez et al, 2008). Dietary intervention with preboitics increased
Bifidobacteria which was negatively correlated with LPS concentration and positively
correlated with improved glucose tolerance and glucose stimulated insulin secretion in
high fat induced obese mice (Cani et al, 2007c).
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•

Modulation of Energy Homeostasis through Regulating Host Genes
Studies of germ-free mice have indicated the addition of microbiota prompted the

host to produce glucose and triacyglycerol in the liver. Fasting-induced adipose factor
(FIAF) was a key modulator involved in this fat storage. FIAF can inhibit lipoprotein
lipase activity, therefore, when it is suppressed by gut microbiota , the activated
lipoprotein lipase promotes release of fatty acids and triacyglycerol which are taken up
by adipose tissue(Backhed et al, 2004). In addition, Backhed and colleagues observed
that the fatty acid metabolism was increased in germ-free mice. They demonstrated two
possible mechanisms that 1) elevated FIAF stimulated the synthesis of peroxisome
proliferator activated receptor gamma coactivator which up-regulates expression of gene
encoding enzymes in fatty acid oxidation; 2) increased level of AMP-activated protein
kinase activity which would promote fatty acid oxidation (Backhed et al, 2007).
Modulation of gut microbiota via specific dietary fibers and subsequent upregulation of
gut peptide gene expression as well as elevation in plasma is another mechanism
proposed (Zhou et al, 2006; Zhou et al, 2009;Cani et al, 2006). Gut hormone such as
GLP-1 and PYY are well documented in favor of weight loss and glycemia control
(Drab.2010; Horton et al, 2010; Gautier et al, 2008).

66

CHAPTER 3
DIETARY RESISTANT STARCH IMPROVES MATERNAL GLYCEMIC
CONTROL IN GOTO-KAKIZAKI RAT
3.1 Introduction
With the explosion of diabetes reaching epidemic proportion, maternal
hyperglycemia is becoming a health threat to pregnant women worldwide, which consists
of diabetic pregnant women and those diagnosed with Gestational Diabetes Mellitus
(GDM). Maternal hyperglycemia increases risks in labor for mothers. Studies also
showed by contributing to the abnormal fetal environment, maternal hyperglycemia may
predispose offspring to develop metabolic disorders (Hillier et al, 2007; Boney et al,
2005). Approaches for treatment of maternal hyperglycemia are limited due to safety
concerns for the fetus.
RS are dietary carbohydrates that resist digestion in the small intestine and reach
the large intestine where they are fermented by bacteria to produce short chain fatty acids.
We have shown that feeding resistant starch decreases body fat accumulation in rodents,
increases gut GLP-1 gene expression and plasma level, and improves glucose tolerance
in STZ-induced diabetic mice (Keenan et al, 2006; Zhou et al, 2006; Zhou et al, 2008).
However, the effects of dietary resistant starch on maternal hyperglycemia remain
unknown. In this study, therefore, we measured the impact of RS feeding on improving
glycemic control in pregnant type 2 diabetes rats-GK rats. Additionally, we focused on
identification of the primary factors underlying the mechanism involved.
3.2 Methods and Materials
3.2.1 Animals and Diet
Twenty female Goto-Kakizaki rats aged 5 weeks and weighing 80~100g along
with 10 age matched female Wistar rats at the beginning of the study, were obtained from
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Charles River (Wilmington, MA). They were housed individually in hanging wire-mesh
cages in a temperature-controlled room (22±1 oC) on a 12 h/12 h light/dark cycle with the
light on at 7am. Rats were acclimated for 1 week to a powdered diet and to the cages.
Water and assigned diet were available ad libitum during the experiment except as noted.
The protocols were approved by the Pennington Biomedical Research Institutional
Animal Care and Use Committee.
The composition of the two experimental diets used in this study is listed in Table
3.1. The resistant starch (RS) diet contained 30% (weight/weight) resistant starch (HiMaize® cornstarch; National Starch & Chemical Co., Bridgewater, NJ). The equal
energy density control (EC) diet had 100% amylopectin cornstarch (Amioca®; National
Starch and Chemical Co.) as the carbohydrate source and equal energy density as the RS
diet (3.3kcal/g) by using non-fermentable cellulose (Dyets, Bethlehem, PA) to dilute the
energy density.
3.2.2 Experimental Design
After one week of acclimation, GK rats were randomly grouped and divided into
two diet treatment groups, resistant starch and energy control, stratified by their weight.
Wistar rats served as a genetic control and were fed with energy control diet. The three
groups of rats were fed their assigned diets throughout the experiment. Food intake and
body weight were measured three times per week. After they were on the diets for 70
days, the animals were mated with male Wistar rats by caging two opposite gender rats
together. Pregnancy was confirmed by the presence of a vaginal plug. The rats were
sacrificed via decapitation when pups were weaned. Different fat pads (ovarian fat,
perirenal fat, and remaining fat in the abdominal area, defined as abdominal fat) were
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Table 3.1. Experimental Diet Composition

Ingredients

Control

100% amylopectin

grams

kcal

424.5

1485.8

RS
grams

0

kcal

0

High amylose starch
60% amylose/

0

0

530.7

1486

40%amylopectin
Sucrose

100

400

100

400

Casein

200

716

200

716

Soybean oil

70

591.5

70

591.5

156.2

0

50

0

Mineral mix

35

30.8

35

30.8

Vitamin mix

10

38.7

10

38.7

Choline chloride

1.3

0

1.3

0

L-cystine

3.0

12

3.0

12

Cellulose

1000 g/kg

3.3kcal/g

1000 g/kg

69

3.3kcal /g

removed and weighed. Total body fat used for body fat calculation was the sum of
ovarian fat, perirenal fat, and abdominal fat. The gastrointestinal (GI) tract was removed
weighed after removal of mesenteric fat. Disemboweled weight was calculated by
subtracting GI weight from body weight. The weight of cecal contents was determined
by subtraction of empty cecum weight from full cecum weight.
3.2.3 Plasma Assays
Blood was collected and centrifuged at 4000 X g for 20 minutes to extract serum.
Serum GLP-1 was measured by radioimmunoassay with RIA kits from Linco Research
Inc. (St. Louis, MO). To make the standard curve for GLP-1, 100 ul of the seven
standards (10-1000pM) was mixed with 100ul GLP-1 antibody and 400ul assay buffer in
tubes to incubate overnight at 4 oC. On the second day, 100 ul 125I-Rat GLP-1 was added
into the mixture and incubated overnight at 4 oC. On day three, 10 ul Rabbit Carrier and
1.0 cold precipitating reagent were pipetted into the tubes in turn. After following
incubation and centrifugation, supernatant was decanted from the tubes and radiation
counts were determined with a gamma counter. The counts were regressed on the GLP-1
standard concentration to obtain the standard curve. For the sample measurement, the
same procedure was performed. The GLP-1 concentration in each sample was calculated
using the standard curve, expressed in pM. Serum insulin was measured using rat ELISA
kits from Crystal Chem Inc (Downers Grove, Illinois).
3.2.4 Immunohistochemical Staining and Morphometry
Pancreases were removed from decapitated rats, weighed and fixed in 10%
buffered neutral formalin for at least 48hours and embedded in paraffin. Each pancreatic
block was sectioned serially at 5um throughout the length to avoid any bias. Twelve
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pancreases were examined as total for three groups. Adjacent sections were obtained one
in every 20 sections through the specimen and immunostained for insulin by
immunofluorescent method (Movassat et al, 1997). The sections were deparaffinized and
rehydrated in xylene substitute and ethanol. Blocking buffer was composed of 10%
normal goat serum, 0.3% triton X-100 and phosphate-buffered saline. The primary antiinsulin serum was purchased from Invitrogen Corporation (CA, USA). It was a guinea
pig anti-porcine insulin serum with1:200 dilutions in PBS. The second antibody was
Alexa Fluor 488 goat anti-guinea pig immunoglobulin at a concentration of 5 ug/ml
diluted in PBS, also from aforementioned company. The sections were visualized using
fluorescence microscopy. Counterstaining with haematoxylin was performed on each
section to facilitate nuclear identification. Quantitative evaluation was performed using
nanozoomer digital pathology software (Hamamatsu, Japan). The areas occupied by
insulin positive cells as well as the area of the total pancreatic cells were analyzed in each
section. The average percent of beta cells to the total pancreatic area of each section was
calculated as relative beta cell density.
3.2.5 Cecal Butyrate Producing Bacterial mRNA Expressions
•

DNA Extraction
DNA was extracted using a QIAamp DNA Stool Mini kit (QIAGEN, Valencia,

CA) using the manufacturer's instructions with slight modifications shown below. An
amount of 180-220 mg cecal contents was weighted in a 2ml microcentrifuge tube and
placed on ice. Buffer ASL, 1.4ml, was added to each sample and vortexed continuously
for 1 min. The following steps were performed at room temperature. The suspension was
heated for 5min at 95 oC, and then frozen in liquid nitrogen. The heat-freeze cycle was
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repeated three times. After being vortexed for 15s and centrifuged at full speed for 1 min
to pellet particles, 1.2 ml of supernatant was removed into a new 2ml microcentrifuge
tube. One inhibitEX tablet was put into each sample and vortexed immediately and
continuously for 1 min or until the tablet was completely suspended. The suspension was
then incubated for 1 min at room temperature to allow the inhibitor to absorb the
inhibitEX matrix. Centrifuging at full speed for 3 min before and after the supernatant
was removed into a new 1.5 microcentrifuge tube. Proteinase K, 15 ul, was pipeted into a
new microcentrifuge tube with 200 ul supernatant. After adding 200 ul buffer AL, the
tube was incubated at 70 oC for 10 min. then the solution in the tube was mixed with
200ul of 100% ethanol, and the lysate was put into a spin column. The DNA was washed
with 500ul buffer AW1 and 500ul buffer AW2 respectively; a one-minute spin at full
speed was applied after a wash and a 3-minute spin for the last wash. Then the column
was moved to a 1.5-ml collection tube, and 200 ul of buffer AE was added directly onto
the fiber matrix. After a 1-minute incubation at room temperature, the cup was spun for 1
min. For DNA quantification, 1.5 ul of sample DNA was used to detect the optical
density (OD) at OD260 and OD280 using a nanodrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Inc. DE, USA).
•

Quantitative Real-time PCR
The gene transcription for butyrate producing bacteria was determined using the

SYBR® Green method of quantitative real–time PCR (qRT-PCR) assay, and results were
expressed as a relative fold change of control. The sequences of the primers for targeted
bacterial groups are listed in Table 3.2. Real time RT-PCR reaction mixture was 10 ul of
total volume, including 3 µl of DNA sample, 5µl of 2X SYBR Green Master Mix
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(Applied Bio systems, Foster City, CA,USA), 0.5 µl of reverse/forward primers at 10 µM,
0.5 µl of bovine serum albumin (BSA) (final concentration 2.5 mg/ml), and 0.5 µl of
nuclease free water. All reactions were performed in sterile MicroAmp® optical 384-well
reaction plates (Applied Biosystems, Foster City, CA). The reaction condition is 50°C for
2 min, 95°C for 10 min for one cycle, then 40 cycles of 95°C for 15 s, 60°C for 1 min,
then 78°C for 30 s. The dissociation step was included to verify specificity through
analyzing the melting curve of the amplified product.
3.2.6 Measurement of UCP-1 mRNA Expression
RNA was extracted from brown adipose tissue using Trizol from Sigma (St.
Louis, MO). The gene transcription for UCP-1was determined using real-time reverse
transcriptase polymerase chain reaction, and results were expressed as a ratio to the
expression of the constitutive gene cyclophilin. The sequence of the primers and probe
for rat cyclophilin is listed in Table 3.2. The probe and primers for UCP-1
(assay identification no. Rn00562126_m1) were purchased from Applied Biosystems
(Foster City, CA).Real time RT-PCR reaction mixture was 10 ul of total volume,
including 9ng of sample RNA, 1 ul of 10 X Taqman buffer, 5.5mM MgCl2, dATP,
dCTP, dUTP and dGTP each 0.3 mM, 500 nM forward primers, 500 nM reverse primers,
200 nM Taqman probes, 7.5 U RNase inhibitor, 5 U MuLV reverse transcriptase, 0.3 U
AmpliTaq Gold DNA polymerase and RNase-free H2O. Each sample was tested in
duplicate. The one-step real-time reverse transcriptase polymerase chain reaction
condition is 48 oC for 30 min, 95oC for 10 min for one cycle, 95 oC for 15 sec and 60 oC
for 1 min for 40 cycles.
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Table 3.2 The sequences of primers for real time RT-PCR. F: forward primer, R:
reverse primer, P: probe.

Gene
16S universal primers

Sequence
F - TGSTGCAYGGYYGTCGTCA
R -ACGTCRTCCMCNCCTTCCTC

Bifidobacterium spp

F –GGGTGGTAATGCCGGATG
R- TAAGCCATGGACTTTCACACC

Bacteroidetes

F -GAA GGT CCC CCA CAT TG
R- CAA TCG GAG TTC TTC GTG

Lactobacillus spp

F -TGG ATG CCT TGG CAC TAG GA
R- AAA TCT CCG GAT CAA AGC TTA CTT AT

Clostridial cluster IV

F- TTA CTG GGT GTA AAG GG
R- TAG AGT GCT CTT GCG TA

Clostridium cluster XIV

F- AAA TGA CGG TAC CTG ACT AA
R- CTT TGA GTT TCA TTC TTG CGA

Cyclophilin

F- 5'CCCACCGTGTTCTTCGACAT3'
R- 5'TGCAAACAGCTCGAAGCAGA 3'
P- 5'CAAGGGCTCGCCATCAGCCG 3'
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3.2.6 Oral Glucose Tolerance Test
The oral glucose tolerance test was performed in female rats on the 16th day of
gestation. After an overnight fast, a blood sample was collected for insulin measurement.
Blood glucose was measured prior and 30, 60, 120 minutes after the administration of
glucose (2.0 g/kg body weight) with a glucometer (Abbott Laboratories, North Chicago,
IL). HOMA-IR was calculated to indicate insulin sensitivity.
3.2.7 Pancreatic Insulin Content
Approximately 150mg of pancreas was weighed and placed into 2ml Acid-Ethanol
solution (75% ethanol, 1.5%HCL 12N, 23.5% distilled water). After an overnight
incubation at -20 oC, the tissue was homogenized at 4 oC and then underwent another
overnight incubation at –20°C. The diluted supernatant was used to determine insulin
content by ELISA (Crystal Chem Inc., Downers Grove, Illinois, USA).
3.2.8 Cecal Contents pH and Short Chain Fatty Acid Analysis
Cecal contents (0.5 gram) was weighed and put into a plastic centrifuge tube with
4.5 ml of distilled water. The sample was mixed throughly by vortex and pH was
measured using a pH meter. The sample was centrifuged at 4°C at 8000 RPM for at least
10 min and filtered through a Millipore syringe filter. The supernatant was transferred to a
vial and the vial stored at 0OC until short fatty acids were quantitated by gas
chromatography.
3.2. 9 Statistical Analysis
Data are presented as means ±SEM. Statistical analyses were performed using the
Statistical Analysis System (SAS 9.1). One way ANOVA and student ttest were used to

75

examine the influence of treatment on all measurements. Subgroup means were compared
by Tukey’s method.
3.3 Results
3.3.1 Fat Pads Weights
Compared with GK rats fed the control diet, dietary resistant starch significantly
decreased fat/disemboweled weight (p<0.05) (Figures 3.1).
3.3.2 Insulin Sensitivity and Fasting Glucose Levels
Dietary resistant starch improved insulin sensitivity in pregnant GK rats as
indicated by HOMA-IR. Also resistant starch fed pregnant GK rats had lower fasting
glucose and fasting serum insulin concentrations compared with EC fed GK rats (p<0.05)
(Figures 3.2). However there was no difference found in ΔAUC between these two
groups.
3.3.1 Immunohistochemistry and Pancreatic Insulin Content
There were fewer islets in the GK groups than in normal Wistar rats; the GK-EC
rats had the least. RS-GK rats had more pancreatic insulin than EC fed GK rats (p<0.05).
The beta cell relative densities were 0.758 ±0.064% in Wistar rats, 0.301 ±0.024% in
GK-EC rats, and 0.56±0.037% in GK-RS rat, respectively (p<0.05). In the GK-EC rats,
the large islets displayed disrupted configuration, irregular capsules and cells of unevenly
being stained with the anti-insulin sera. In contrast, islets in Wistar rats were round in
shape, clearly boundary defined, and homogeneously stained beta cells (Figure 3.3).
3.3.4 Cecal Content pH and Short Chain Fatty Acids
The pH values for both cecal contents and feces were lower in RS fed pregnant GK
rats, whereas the weights of full GI and cecal content were higher in RS fed pregnant GK
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rats than EC fed GK rats (p<0.05) (Figure 3.4). Short chain fatty acid concentrations
including acetate, butyrate and propionate, were elevated in cecal contents of pregnant
GK rats fed RS (p<0.05) (Figure 3.7).
3.3.5 Microflora Expressions in Cecum
The microflora engaged in converting resistant starch to butyrate are Bacteroides
spp, Bifidobacterium spp, Lactobacillus spp, Clostridial cluster IV and Clostridial cluster
XIV (Bird et al, 2000; Xu et al, 2003a; Louis et al, 2007b; Louis et al, 2007a; Sato et al,
2008). The population of bacteria involved in butyrate production in the cecum was
increased in RS fed pregnant GK rats. Bacteroides, Bifidobacterium, Lactobacillus and
Clostridial cluster IV population were increased compared with those in EC fed GK rats
(p<0.05) (Figure 3.5, 3.6). No significant difference was observed in Clostridial cluster
XIV.
3.3.6 Serum GLP-1 Concentration and UCP-1 Gene Expression in BAT
The total serum GLP-1 concentration was increased in GK rats fed with RS,
compared with GK rats fed with EC (p<0.05) (Figures 3.8). There was a trend of
increased mRNA expression of UCP-1 in brown adipose tissue of rats fed with RS
(p=0.08).
3.3.7 Food intake and Disemboweled Weight
There were no statistical differences in food intake between control and RS fed rats.
This demonstrated no or minimal discomfort with the consumption of resistant starch at
the levels fed. Because RS fed rats had significantly heavier GI contents, the
disemboweled body weight was used to exclude GI contents from body weight. There
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Figure 3.1 Percentages of body fat/ disemboweled body weight in GK rats fed with
resistant starch or energy control diet. Data are mean ± SEM for group of 10 rats. *
P<0.05 vs. EC treated GK rats.
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Figure 3.2 Fasting glucose concentrations (a), fasting serum insulin levels (b) and
HOMA-IR (c) measured on the 16th day of gestation in GK rats fed with RS or EC diet
and Wistar rats fed on EC. Data are mean ± SEM for group of 10 rats. * P<0.05 vs. ECGK.
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Figure 3.3 Beta cell densities and pancreatic insulin contents in GK rats fed with RS or
EC diet and Wistar rats fed on EC diet. Data are mean ± SEM. * P<0.05 vs. EC-GK.
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Figure 3.4 Cecal content pH(a), feces pH values (b), full GI weight (c) and cecal content
weight (d) in GK rats fed with RS or EC diet and Wistar rats fed on EC diet. Data are
mean ± SEM for group of 10 rats. * P<0.05 vs. EC-GK.
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Figure 3.5 Fold changes of Bacteroides spp (a) and Bifidobacterium spp (b) measured
with RT-PCR in GK rats fed with RS or EC diet. Data are mean ± SEM for group of 10
rats. * P<0.05 vs. EC-GK.
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Figure 3.6 Fold changes of Lactobacillus spp (a), Clostridial cluster IV(b) and Clostridial
cluster XIV (c) were measured with RT-PCR in GK rats fed with RS or EC diet . Data
are mean ± SEM for group of 10 rats. * P<0.05 vs. EC-GK.
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Figure 3.7 Cecum short chain fatty acids concentrations were measured in GK rats fed
with RS or EC diet and Wistar rats on EC for 18 weeks. Data are mean ± SEM for group
of 10 rats. * P<0.05 vs. EC- GK.
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Figure 3.8 Serum total GLP-1 concentrations in GK rats fed with RS or EC diet and
Wistar rats on EC diet for 18 weeks. Data are mean ± SEM for group of 10 rats. *
P<0.05 vs. EC- GK.
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Table 3.3 Food intakes and disemboweled body weight
Group
GK-EC
GK–RS

Cumulative food intake (g)

Disemboweled body weight (g)

1442.0±36.0
1565.6±52.9

274±5.1
262±6.55

GK-EC: GK rats fed control diet
GK-RS: GK rats fed resistant starch diet
Food intake and disemboweled body weight of GK rats fed with RS or EC diet for 18
weeks. Data are mean ± SEM for group of 10 rats
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was no significant difference for disemboweled body weight between control and RS fed
rats (Table 3.3)
3.4 Discussion
In this study, we investigated the effects of dietary resistant starch on improving
maternal hyperglycemia. Our results demonstrated that dietary resistant starch increases
insulin sensitivity and pancreatic beta cell mass in pregnant GK rats, a non obesity type 2
diabetes model featured with reduced beta cell mass and defective insulin response to
glucose (Portha, 2005; Movassat et al, 1997; Movassat et al, 2007; Movassat et al, 1995).
Specifically, we measured fat pad changes, fasting insulin and glucose concentration,
pancreatic insulin content and beta cell density in the pregnant GK rats in the context of
resistant starch feeding. To our knowledge, our findings provide the first direct evidence
that dietary resistant starch alters pancreatic beta cell density in GK rats.
Feeding resistant starch to pregnant GK rats significantly increased insulin sensitivity.
The result is consistent with the observation that RS fed rats had reduced fat pads. The
decreased body fat in RS fed rats is most likely the result of increased energy expenditure.
Human studies have shown fatty acid oxidation is significantly increased after
consumption of resistant starch (Higgins et al. 2004). Our previous data also suggested
dietary resistant starch enhanced energy expenditure in mice (Zhou et al, 2008). It
increased the expression of POMC in the arcuate nucleus of the hypothalamus in rats
(Shen et al, 2009) which is critical in promoting energy expenditure (Xu et al, 2006), and
increased protein expression of adiponectin in white adipose tissue (unpublished data).
We found the butyrate levels were elevated in the cecal contents of GK rats with the
feeding of resistant starch. Gao and his coworkers reported that the addition of sodium
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butyrate in diet led to improved insulin sensitivity, facilitated fatty oxidation and
increased energy expenditure in mice; it protected mice from diet induced obesity (Gao et
al, 2009). Different from the butyrate in diet, butyrate from fermentation has local effect
in the lower gut where butyrate is avidly absorbed by the colonocytes and L-endocrine
cells to stimulate GLP-1 expression (Zhou et al, 2006). Some butyrate may reach the liver
to inhibit hepatic lypolysis (unpublished data). However, whether the butyrate from
fermentation enters systemic blood is still uncertain. Therefore, the effect of the butyrate
from fermentation may be indirect through the production of gut hormones. GLP-1 is
reported to increase energy expenditure. Higher fasting plasma GLP-1 levels are
associated with higher rates of energy expenditure and fat oxidation in human subjects
(Osaka et al, 2005). It has also been reported that GLP-1 plays a role in postprandial
energy expenditure and that GLP-1 stimulates POMC neurons in the arcuate nucleus via
GLP-1 receptors (Ma et al, 2007). We found a trend of increased UCP-1 expression in
resistant starch fed GK rats, compared with EC fed GK rats, which is in accordance with
what Aziz et al reported. They observed a high amylose starch diet led to higher insulin
sensitivity index (QUICKI), and elevated mRNA expression of UCP-1 in diet induced
obese rats (Aziz et al, 2009). UCP-1 diverts energy from ATP synthesis to thermogenesis
through which increases energy expenditure (Puigserver et al, 1998).
Another major finding is that feeding resistant starch significantly increased
pancreatic insulin content and beta cell density in pregnant GK rats. This result raises an
interesting question: what causes such changes in resistant starch fed GK rats? Resistant
starch potentially has three major effects as a part of the diet: metabolizable energy
dilution, a bulking effect, and fermentation to produce short-chain fatty acids and
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increase GLP-1 (Keenan et al. 2006; zhou et al, 2008). In our study, control and resistant
starch diets have the same energy density, so the energy dilution effect can be excluded.
The bulking effect is the prevention of food intake caused by gastrointestinal distension
(Phillips et al. 2000). But our results indicated there was no difference in food intake
between resistant starch fed GK rat and EC fed rats. Thus, the hypothesis most likely for
the mechanism of increased pancreatic insulin content and beta cell density was narrowed
down to the fermentation of resistant starch and the subsequent increases of GLP-1.
Elevated plasma GLP-1 was previously observed before in both normal SD and diet
induced obese rats fed resistant starch (Shen et al, 2009; Aziz et al, 2009). The GLP-1
increase is consistent over a 24 hour period in SD rats (Zhou et al, 2008). Gut gene
expression data from our group also verified that dietary RS dramatically up-regulated
the expression of the GLP-1 gene in rat cecal cells compared to rats consuming an energy
control diet (Zhou et al, 2006).
In order to clarify the process from dietary resistant starch fermentation
accociated with increased production of GLP-1 in resistant starch fed pregnant GK rats,
we investigated several important steps in fermentation. Firstly, we measured cecal and
fecal pH values, cecal content weight, and found the existence of fermentation
demonstrated by the decrease of pH values as well as increased cecal content weight in
resistant starch fed GK rats. Secondly, augmented butyrate producing bacterial
population was confirmed except for Clostridial cluster XIV which might be due to its
absolute reduction in type 2 diabetes (Larsen et al, 2010). Third, short chain fatty acids
including acetate, butyrate and propionate were elevated in resistant starch fed GK rats.
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Finally, an increase of plasma GLP-1 was indentified. Our previous study has indicated
butyrate promoted GLP-1 expression in vitro (Zhou et al, 2006).
The action of GLP-1, as a potent incretin, includes stimulating proinsulin gene
expression (Drucker et al, 1987), inhibiting glucagon secretion (Nauck et al, 2002). It
also mediates glucose-dependent insulin secretion via their receptors expressed on beta
cell (Drucker, 2006), inhibits gastric acid secretion and delays gastric emptying(Baggio et
al, 2004), as well as promotes an increase in pancreatic β-cell mass through enhancing
beta cell proliferation and inhibiting apoptosis (Stoffers et al, 2003;Wang et al, 2002).
GLP-1 was shown to be able to delay the onset of type 2 diabetes and improve
pancreatic insulin content and total beta-cell mass in GK rats when applied postnatally
for 5 days (Tourrel et al, 2002). This hormone was also reported to reduce apoptosis in
human islets (Farilla et al, 2003). A GLP-1 receptor agonist demonstrated similar effects.
Extendin-4 not only improved glucose tolerance in diabetic rats via expansion of beta cell
volume (Xu et al, 1999), but also prevented the development of diabetes in rats exposed
to intrauterine growth retardation (Stoffers et al, 2003). Further studies are needed for a
conclusive determination for the role of increased GLP-1 in dietary resistant starch
induced improvement on glycemic control in pregnant GK rats.
In conclusion, dietary resistant starch improved insulin sensitivity, pancreatic
insulin content and beta cell density in pregnant GK rats. The increased production of
GLP-1 resulting from fermentation of resistant starch was linked to the mechanism of
improved glycemic control in pregnant GK rats. Our findings provide further evidence
that resistant starch works as a natural agent to treat maternal hyperglycemia.
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CHAPTER 4
FEEDING DIETARY RESISTANT STARCH TO GOTO-KAKIZAKI RAT
IMPROVES FASTING GLUCOSE IN OFFSPRING
4.1 Introduction
The observation of adult type 2 diabetics having higher incidence of type 2
diabetes in mothers than that on the paternal side suggested the role of abnormal fetal
environment in the development of metabolic disorders (Dorner et al, 1976). Over the
years, there is a growing body of evidence indicating intrauterine exposure to a
hyperglycemic environment increased the risk of diabetes and obesity for offspring later
in their life in addition to genetic transmission (Ezekwe et al, 1980; Kasser et al, 1981;
Hausman et al, 1982; Pettitt et al, 1991; Waterland et al, 1999; Boney et al, 2005). A
study also revealed that glycemic control in GDM pregnancies is an effective way to
prevent impaired glucose tolerance in childhood. Even minimal intervention will make a
difference (Malcolm et al, 2006).
RS are dietary carbohydrates that resist digestion in the small intestine and reach
the large intestine where they are fermented by bacteria to produce short chain fatty acids.
Previous work from our lab has shown that feeding resistant starch to pregnant GK rats
improved insulin sensitivity and hyperglycemia. In this study, therefore, we investigated
the offspring of GK rats that had been fed a RS diet or energy control diet from 6 weeks
old throughout adult life and pregnancy. All offspring were weaned on a standard chow
diet. Food intake, insulin sensitivity, pancreatic insulin content and beta cell mass of the
offspring were determined.
Due to its ability to resist being broken down completely by digestive enzymes, it
was reported that dietary resistant starch in the diet was accompanied by gastrointestinal
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effects including flatus, abdominal discomfort, and diarrhea, which could exert a negative
impact on gestation and fetal growth (Grabitske et al, 2009).Therefore, pup size, the
growth curve and fat pad weights were observed to elucidate these possibilities.
4.2 Methods and Materials
4.2.1 Animals and Diet
Twenty female Goto-Kakizaki rats aged 6 weeks from Charles River (Wilmington,
MA) were housed individually and fed either the resistant starch diet or energy control
diet for 10 weeks before they were mated. Ten age -matched female Wistar rats were fed
the energy control diet. All animals (GK-EC, GK-RS, and Wistar-EC) were in a
temperature-controlled room (22±1 oC) on a 12 h/12 h light/dark cycle with the light on
at 7am with free access to water and assigned diet. The protocols were approved by the
Pennington Biomedical Research Institutional Animal Care and Use Committee.
The composition of the two experimental diets used in this study is listed in Table
3.1. The resistant starch (RS) diet contained 30% (weight/weight) resistant starch (HiMaize® cornstarch; National Starch & Chemical Co., Bridgewater, NJ). The equal
energy density control (EC) diet had 100% amylopectin cornstarch (Amioca®; National
Starch and Chemical Co.) as the carbohydrate source and an equal energy density as the
RS diet (3.3kcal/g) by using non-fermentable cellulose (Dyets, Bethlehem, PA) to dilute
the energy density.
After rats in these three groups delivered, their pups were weighed and litter size
reduced to 6 pups. Ten pups from each group were randomly chosen and raised to 8
weeks old on standard chow diet (#5001, Dietlab, USA). Food intake and body weight
were measured three times a week. Upon being decapitated, different fat pads
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(epididymal fat, perirenal fat, and abdominal fat) were removed and weighed. Total
abdominal body fat used for body fat calculation was the sum of epididymal fat, perirenal
fat, and abdominal fat. The gastrointestinal (GI) tract was removed and weighed after
removal of mesenteric fat. Disemboweled weight was calculated by subtracting GI
weight from body weight. The weight of the cecal contents was determined by
subtraction of empty cecum weight from full cecum weight.
4.2.2 Plasma Assays
Blood was collected and centrifuged at 4000 X g for 20 minutes to extract serum.
Serum insulin was measured using rat ELISA kits from Crystal Chem Inc (Downers
Grove, Illinois).
4.2.3 Immunohistochemical Staining and Morphometry
Pancreases were removed from decapitated rats, weighed and fixed in 10%
buffered neutral formalin for at least 48hours and embedded in paraffin. Each pancreatic
block was sectioned serially at 5um throughout the length to avoid any bias. Twelve
pancreases were examined as total for three groups. Adjacent sections were obtained
with one in every 20 sections through the specimen and immunostained for insulin by
immunofluorescent method (Movassat et al, 1997). The sections were deparaffinized
and rehydrated in xylene substitute and ethanol. Blocking buffer was composed of 10%
normal goat serum, 0.3% triton X-100 and phosphate-buffered saline. The primary antiinsulin serum was purchased from Invitrogen Corporation (CA, USA). It was a guinea
pig anti-porcine insulin serum with a 1:200 dilutions in PBS. The second antibody was
Alexa Fluor 488 goat anti-guinea pig immunoglobulin at aconcentration of 5 ug/ml
diluted in PBS, also from the aforementioned company. The sections were visualized
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using fluorescence microscopy. Counterstaining with haematoxylin was performed on
each section to facilitate nuclear identification. Quantitative evaluation was performed
using nanozoomer digital pathology software (Hamamatsu, Japan). The area occupied
by insulin positive cells as well as the area of the total pancreatic cells was analyzed in
each section. The average percent of beta cells to the total pancreatic area of each
section was calculated as relative beta cell density.
4.2.4 Oral Glucose Tolerance Test
An oral glucose tolerance test was performed in pups when they were 56 days old.
After an overnight fast, a tail vein blood sample was collected for insulin measurement.
Blood glucose was measured prior and 120 minutes after the administration of glucose
(2.0 g/kg body weight) with a glucometer (Abbott Laboratories, North Chicago, IL).
HOMA-IR was calculated to indicate insulin sensitivity.
4.2.5 Pancreatic Insulin Content
Approximately 150mg of pancreas was weighed and placed into 2 ml of AcidEthanol solution (75% ethanol, 1.5%HCL 12N, 23.5% distilled water). After an
overnight incubation at -20 oC, the tissue was homogenized at 4 oC and then underwent
another overnight incubation at –20°C. The diluted supernatant was used to determine
insulin content by ELISA (Crystal Chem Inc., Downers Grove, Illinois, USA).
4.2.6 Cecal Content pH Measurement
Cecal contents, 0.5 grams, were weighed and put into a plastic centrifuge tube with
4.5 ml of distilled water. The sample was mixed throughout by vortexing and the pH was
measured using a pH meter.
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4.2.7 Statistical Analysis
Data are presented as means ± SEM. Statistical analyses were performed using the
Statistical Analysis System (SAS 9.1). One way ANOVA and student ttest were used to
examine the influence of treatment on all measurements. Subgroup means were
compared by Tukey’s method.
4.3 Results
4.3.1 Fat Pads Weights
There were no significant differences found in percentages of body fat/ body
weight between pups born to RS fed GK rats and EC fed GK rats (Figures 4.1).
4.3.2 Insulin Sensitivity and Fasting Glucose Levels
Pups born to dietary resistant starch fed GK rats had lower fasting glucose
compared with offspring from EC fed GK rats (p<0.05) (Figure 4.2). However there was
no difference found in fasting serum insulin concentration, 2- hour glucose level and
insulin sensitivity (HOMA-IR) between these two groups.
4.3.1 Immunohistochemistry and Pancreatic Insulin Content
Pancreatic insulin content was increased in pups born to resistant starch fed GK
rats compared to those born to EC fed GK rats. No significant difference was found in
beta cell density between offspring from the two groups (Figure 4.3).
4.3.4 Cecal Content pH
The pH value for cecal contents was not significantly different between pups born
to GK rats on the resistant starch or the EC diet. Offspring from resistant starch fed GK
rats showed lower weight of cecal contents (p<0.05) (Figure 4.4). As indicated by cecal
content weight and pH value, there was no fermentation difference in the cecum between
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Figure 4.1 Different fat pads (epididymal fat, perirenal fat, and abdominal fat) were
removed and weighed from pups from GK-RS, GK-EC and Wistar-EC dams. Total body
fat used for body fat calculation was the sum of epididymal fat, perirenal fat, and
abdominal fat. Data are mean ± SEM for group of 10 rats.
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Figure 4.2 Fasting glucose and insulin concentrations as well as HOMA-IR were
measured in 8 weeks old pups from GK-RS, GK-EC and Wistar-EC dams. Data are
mean ± SEM for group of 10 rats. * P<0.05 vs. EC-GK.
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Figure 4.3 Pancreatic insulin contents (left) and Beta cell density (right) were measured
in 8 weeks old pups born to GK-RS, GK-EC and Wistar-EC dams. Data are mean ± SEM.
* P<0.05 vs. EC-GK.
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Figure 4.4 Cecum content pH and cecum content weight were measured in 8 weeks old
pups born to GK-RS, GK-EC and Wistar-EC dams. Data are mean ± SEM for group of
10 rats. * P<0.05 vs. EC-GK.
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Figure 4.5 Growth curves of pups. No significant difference was detected between
offspring of GK rats fed resistant starch and EC diet. Data are mean ± SEM for group of
10 rats.
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Table 4.1 Food intakes and disemboweled body weights of offspring
Group
GK-EC
GK–RS

Cumulative food intake (g) Body weight (g)
630.0±10.3
596.1±28.6

268.7±5.9
268.0±7.3

Litter size
8.2±1.4
9.11±1.6

GK-EC: Pups born to GK rats fed control diet
GK-RS: Pups born to GK rats fed resistant starch diet
There were no significant difference in food intake, body weight and litter size between
pups born to control and RS fed GK rats. Data are mean ± SEM for group of 10 rats.
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the two groups, so short chain fatty acids concentrations and microfloral population were
not measured.
4.3.5 Food intake and Body Weight
There were no statistical differences in litter size between pups born to control and
RS fed GK rats. It demonstrated no or minimal side effect on pregnancy with the
consumption of resistant starch at the levels in their diet. No significant differences for
body weight and food intake were found between offspring from control and RS fed GK
rats (Table 4.1). No significant difference was detected in growth rate between offspring
of GK rats fed resistant starch and EC diet (Figure 4.5).
4.4 Discussion
In this study, we investigated the effect of feeding dietary resistant starch to GK
dams on glucose metabolism of their offspring. We demonstrate that offspring of GK rats
fed resistant starch had lower fasting glucose levels and increased pancreatic insulin
content compared with pups from dams fed the EC diet. In addition, we measured birth
rate and growth of pups born to dams fed on both diets, and found there were no adverse
effects observed on offspring when feeding resistant starch to dams.
As we predicted, there was no carry over fermentation that occurred in the hind
gut of pups born to resistant starch fed GK dams which was evidenced by the similar
cecal content weight and pH values obtained in both offspring. Therefore, the
improvement of fasting glucose was not ascribed to postnatal elevation of short chain
fatty acids, augmentation of GLP-1 and consequent enhanced insulin sensitivity.
Moreover, we have shown that insulin sensitivity was not improved in pups of GK dams
fed on resistant starch.
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During the last few years, it has been suggested that the experience of
hyperglycemia may contribute to an endocrine pancreas defect in the offspring (Simmons,
2006). Although the development of diabetes in GK rats results from both genetic and
environmental determinants, Gauguier and coworkers (Gauguier et al, 1994) reported that
offspring of GK females crossed with Wistar males had a more marked hyperglycemia
than those of Wistar females crossed with GK males, suggesting a role of the intrauterine
environment. However, not all studies agreed with this conclusion (Abdel-Halim et al.,
1994). Gill-Randall and co-workers developed a rat embryo transfer technique to
examine the weight of genetic factors and intrauterine hyperglycemia (Gill-Randall et al,
2004). They showed that Wistar embryos implanted into the uterus of GK mothers were
more hyperglycemic in adulthood than those tht were reared in Wistar mothers (GillRandall et al, 2004), this clearly illustrating the notion that intrauterine hyperglycemic
environment is a risk factor for developing hyperglycemia in offspring at adulthood.
Impaired gene expression and disturbed organogenesis attributed to increased oxidative
stress (Loeken et al, 2006; Zhao et al, 2005) and reduced angiogenesis induced by
hyperglycemia (Larger et al, 2004) are potential mechanisms associated with this
anomaly. Tight glycemic control before conception and intensive glucose control
maintained during pregnancy is suggested by ADA in order to reduce the prevalence of
type 2 diabetes in offspring (American Diabetes Association, 2004).
In this study, we showed that feeding resistant starch to GK dams resulted in
lower fasting glucose and enhanced pancreatic insulin content. These favorable effects
may result from the improvement of maternal hyperglycemia which in turn changes the
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intrauterine environment. Our findings provide evidence to apply resistant starch as an
intervention in prevention and treatment of diabetes.
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CHAPTER 5
CONCLUSIONS
The work in this dissertation focuses on the effects of dietary resistant starch
on glycemic control in pregnant GK rats and the impact passed on to their offspring.
We measured fat pad changes, fasting insulin and glucose concentration, insulin
sensitivity, pancreatic insulin content and beta cell mass in the pregnant GK rats in the
context of resistant starch feeding. We showed that feeding resistant starch
significantly improved fasting glucose, increased insulin sensitivity and pancreatic
beta cell mass in pregnant GK rats, a non obesity type 2 diabetes model. We further
demonstrated that feeding resistant starch to pregnant GK rats decreased fasting
glucose of their offspring without negative influences on growth and fetus survival
rate.
We provide evidence to indicate that dietary resistant starch was able to
improve pancreatic insulin content and beta cell mass in pregnant GK rats. The
favorable effects of dietary resistant starch in pancreas islets might partly be through
the elevation of GLP-1which is stimulated by increased cecal short chain fatty acid
resulted from promoting gut butyrate producing microbes with resistant starch. Further
work is needed to for a conclusive determination for the role of increased GLP-1 in
dietary resistant starch induced improvement on glycemic control in pregnant GK rats.
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